

**(19) World Intellectual Property Organization
International Bureau**



(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/081631 A2

(51) International Patent Classification⁷: **C12N**

(US). VALLE, Fernando [MX/US]; 1015 Cadillac Way, Apt. 212, Burlingame, CA 94010 (US).

(21) International Application Number: PCT/US02/10575

(74) Agent: ITO, Richard, T.; GENENCOR INTERNATIONAL, INC., 925 Page Mill Road, Palo Alto, CA 94304 (US).

(22) International Filing Date: 4 April 2002 (04.04.2002)

(25) Filing Language: English

(26) **Publication Language:** English

(30) Priority Data:

60/281,618	4 April 2001 (04.04.2001)	US
60/282,259	5 April 2001 (05.04.2001)	US

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): GENENCOR INTERNATIONAL, INC. [US/US]; 925 Page Mill Road, Palo Alto, CA 94304 (US).


(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) **Inventors/Applicants (for US only):** DODGE, Timothy, C. [US/US]; 1384 Bellingham Way, Sunnyvale, CA 94010

[Continued on next page]

(54) Title: UNCOUPLED PRODUCTIVE AND CATABOLIC HOST CELL PATHWAYS



(57) Abstract: The invention provides methods for producing products comprising improved host cells genetically engineered to have uncoupled productive and catabolic pathways. In particular, the present invention provides host cells having a modification in nucleic acid encoding an endogenous enzymatic activity that phosphorylates D-glucose at its 6th carbon and/or a modification of nucleic acid encoding an enzymatic activity that phosphorylates D-gluconate at its 6th carbon. Such improved host cells are used for the production of products, such as, ascorbic acid intermediates. Methods for making and using the improved host cells are provided. Nucleic acid and amino acid sequences for glucokinase and gluconokinase are provided.



Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

UNCOUPLED PRODUCTIVE AND CATABOLIC HOST CELL PATHWAYS

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

5 This invention was made with the United States Government support under Award No. 70 NANB 5H1138 awarded by the United States Department of Commerce. The Government has certain rights in this invention.

TECHNICAL FIELD

10 The present invention relates to engineering of metabolic pathways of host cells and provides methods and systems for the production of products in host cells. In particular, the invention provides methods for producing products in host cells which have been genetically engineered to have uncoupled productive and catabolic pathways.

BACKGROUND ART

15 In the initial stage of host cell carbohydrate metabolism, that is, glycolysis, each glucose molecule is converted to two molecules of pyruvate in the cytosol. The chemical reactions that convert glucose to pyruvate are referred to as the Embden-Meyerhoff pathway. All of the metabolic intermediates between the initial carbohydrate and the final
20 product, pyruvate, are phosphorylated compounds. The final stage of oxidation of carbohydrates, the citric acid cycle, is a complex set of reactions that also takes place in the cytosol. The reactions in the Embden-Meyerhoff pathway and citric acid cycle result in the conversion of carbohydrate molecules to CO₂ molecules with the concomitant reduction of NAD⁺ to NADH molecules and the formation of ATP.

25 The central metabolic routes produce NADH or NADPH. In general NADPH is utilized in biosynthetic reactions and NADH is rapidly reoxidized in two ways:

(1) In fermentative pathways by the direct reduction of organic metabolites.

30 (2) In respiratory processes by electron transport through a respiratory chain to a terminal electron acceptor. This acceptor is usually O₂, but in some cases can be productive ions, including nitrate and sulfate. In all respiratory processes, ATP is generated. Some bacteria possess the ability to oxidize some substrates extracellularly, producing useful oxidation products such as L-sorbose, D-gluconate, keto-gluconates, etc. Such

- 2 -

oxidation reactions are called productive fermentation since they involve incomplete substrate oxidation, accompanying accumulation of corresponding oxidation product in large amounts in the growth medium. The oxidation reaction is coupled to the respiratory chain of the microorganism.

5 (Bacterial Metabolism 2nd Edition (1985) Springer-Verlag, New York, New York).

Bacteria which ferment glucose through the Embden-Meyerhof pathway, such as members of *Enterobacteriaceae* and *Vibrionaceae*, are described in Bouvet, *et al.* (1989) *International Journal of Systematic Bacteriology*, 39:61-67. Pathways for metabolism of ketoaldonic acids in *Erwinia sp.* are described in Truesdell, *et al.*, (1991) *Journal of*
10 *Bacteriology*, 173:6651-6656.

Host cells having mutations in enzymes involved in glycolysis have been described. Yeast having mutations in glucokinase are described in Harrod, *et al.* (1997) *J. Ind. Microbiol. Biotechnol.* 18:379-383; Wedlock, *et al.* (1989) *J. Gen. Microbiol.* 135: 2013-2018; and Walsh *et al.* (1983) *J. Bacteriol.* 154:1002-1004. Bacteria deficient in glucokinase have
15 been described. *Pediococcus sp.* deficient in glucokinase is described in Japanese patent publication JP 4267860. *Bacillus sphaericus* lacking glucokinase is described in Russell *et al.* (1989) *Appl. Environ. Microbiol.* 55: 294-297. *Penicillium chrysogenum* deficient in glucokinase is described in Barredo *et al.* (1988) *Antimicrob. Agents-Chemother* 32: 1061-1067. A glucokinase-deficient mutant of *Zymomonas mobilis* is described in DiMarco *et al.*
20 (1985) *Appl. Environ. Microbiol.* 49:151-157.

Many bacteria possess an active transport system known as Phosphotransferase transport System (PTS) that couples the transport of a carbon source to its phosphorylation. In this system, the phosphoryl group is transferred sequentially from phosphoenolpyruvate (PEP) to enzyme I and from enzyme I to protein HPr. The actual translocation step is
25 catalyzed by a family of membrane bound enzymes (called enzyme II), each of which is specific for one or a few carbon sources. Considering that PTS consumes PEP to phosphorylate the carbon source, and PEP is a central metabolite used in for many biosynthetic reactions, it may decrease the efficiency of conversion of a carbon source into a desired product. This transport system has been replaced by a permease and glucokinase
30 from an heterologous origin as described by Parker *et al.* (1995) *Mol. Microbiol.* 15: 795-802. or homologous origin as reported by Flores *et al.* (1996) *Nat. Biotechnol.* 14: 620-623. In both of these 2 examples, the function of the PTS system for glucose transport and phosphorylation was replaced by a glucose permease and a glucokinase activities.

Products of commercial interest that have been produced biocatalytically in
35 genetically engineered host cells include intermediates of L-ascorbic acid; 1,3-propanediol;

glycerol; D-gluconic acid; aromatic amino acids; 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP); and catechol, among others.

L-Ascorbic acid (vitamin C, ASA) finds use in the pharmaceutical and food industry as a vitamin and antioxidant. The synthesis of ASA has received considerable attention
5 over many years due to its relatively large market volume and high value as a specialty chemical.

The Reichstein-Grussner method, a chemical synthesis route from glucose to ASA, was first disclosed in 1934 (*Helv. Chim. Acta* 17:311-328). Lazarus *et al.* (1989, "Vitamin C: Bioconversion via a Recombinant DNA Approach", *Genetics and Molecular Biology of*
10 *Industrial Microorganisms*, American Society for Microbiology, Washington D.C. Edited by C.L. Hershberger) disclose a bioconversion method for production of an intermediate of ASA, 2-keto-L-gulonic acid (2-KLG, KLG) which can be chemically converted to ASA. This bioconversion of carbon source to KLG involves a variety of intermediates, the enzymatic process being associated with co-factor dependent 2,5-DKG reductase activity (2,5-DKGR
15 or DKGR).

Many bacterial species have been found to contain DKGR, particularly members of the *Coryneform* group, including the genera *Corynebacterium*, *Brevibacterium*, and *Arthrobacter*. DKGR obtained from *Corynebacterium* sp. strain SHS752001 is described in Grindley *et al.* (1988, *Applied and Environmental Microbiology* 54: 1770-1775). DKGR from
20 *Erwinia herbicola* is disclosed in United States Patent No. 5,008,193 to Anderson *et al.* Other reductases are disclosed in United States Patent Nos. 5,795,761; 5,376,544; 5,583,025; 4,757,012; 4,758,514; 5,004,690; and 5,032,514.

1,3-Propanediol is an intermediate in the production of polyester fibers and the manufacture of polyurethanes and cyclic compounds. The production of 1, 3-propanediol is
25 described in United States Patent Nos. 6,025,184 and 5,686,286. 1,3-propanediol can be produced by the fermentation of glycerol. The production of glycerol is described in WO 99/28480 and WO 98/21340.

D-gluconic acid and its derivatives have been used commercially as agents in textile bleaching and detergents. The production of D-gluconic acid in *Bacillus* species lacking
30 gluconokinase activity and having high glucose dehydrogenase activity is described in WO 92/18637.

The production of members of the aspartate family of amino acids is described in United States Patent No. 5,939,307. The production of riboflavin (Vitamin B2) is described in WO 99/61623.

35 Many cyclic and aromatic metabolites are derived from DHAP including tyrosine, tryptophan and phenylalanine. The production of DAHP is described in United States

- 4 -

Patent No. 5,985,617. Catechol is a starting material for the synthesis of pharmaceuticals, pesticides, flavors, fragrances and polymerization inhibitors. The production of catechol is described in United States Patent No. 5,272,073.

However, there are still problems associated with these production methodologies.

5 One such problem is the diversion of carbon substrates from the desired productive pathways to the catabolic pathways. Such diversion results in the loss of available carbon substrate material for conversion to the desired productive pathway products and resultant energy costs, ATP or NADPH, associated with the transport or phosphorylation of the substrate for catabolic pathway use.

10 In spite of the advances made in the production of products by host cells, there remains a need for improved host cells for use in the production of desired products. The present invention addresses that need.

SUMMARY

15 Methods for the production of products in recombinant host cells genetically engineered to have uncoupled productive and catabolic pathways during part or all of the production are provided. The present invention also provides recombinant host cells genetically engineered to comprise productive and/or catabolic pathways that are uncoupled or that can be regulated during production, and methods for their preparation.

20 Accordingly, the invention provides a process for producing a product in a recombinant host cell comprising, culturing a host cell capable of producing said product in the presence of a carbon source under conditions suitable for the production of said product wherein said host cell comprises productive and catabolic pathways, wherein said pathways are uncoupled during part or all of said culturing. In some embodiments, the productive
25 pathway and catabolic pathway are uncoupled during all of said culturing. In some embodiments, the product being produced is a component of the productive pathway or the host cell. In other embodiments, the product being produced is a component of the catabolic pathway of the host cell. In further embodiments, the product being produced is encoded by nucleic acid recombinantly introduced into the host cell.

30 In some embodiments, the productive pathway is in the host cell membrane. In other embodiments, the catabolic pathway is intracellular. In further embodiments, the productive pathway and catabolic pathway are uncoupled at the stage of initial phosphorylation of said carbon source. In additional embodiments, the productive pathway and catabolic pathway are uncoupled at the stage of phosphorylation of a carbon metabolite.

35 In further embodiments, the uncoupling of the productive pathway and catabolic pathway comprises inhibition of at least one enzymatic activity that phosphorylates a carbon

source and/or a carbon metabolite during said culturing. In other embodiments, the uncoupling of said productive pathway and said catabolic pathway comprises inactivation of at least one enzymatic activity that phosphorylates said carbon source and/or a carbon metabolite during part or all of said culturing.

5 In additional embodiments, the host cell comprises a mutation in or deletion of part or all of a polynucleotide that encodes an enzymatic activity that couples an productive pathway with a catabolic pathway. In yet other embodiments, the host cell comprises at least one polynucleotide that lacks the encoding for an enzymatic activity that phosphorylates said carbon source and/or a carbon metabolite wherein said polynucleotide
10 is operably linked to a regulatable promoter.

In some embodiments, the enzymatic activities that are reduced or inactivated are those that phosphorylate D-glucose at its 6th position. In other embodiments, the enzymatic activity that is reduced or inactivated phosphorylates D-gluconic acid at its 6th position. In further embodiments, the enzymatic activity that phosphorylates D-glucose at its 6th carbon
15 includes glucokinase, phosphoenol pyruvate synthase (PEP) or phosphotransferase system (PTS). In additional embodiments, the enzymatic activity that phosphorylates D-gluconate at its 6th carbon includes gluconokinase.

In some embodiments, the product is recovering and in other embodiments, the product is converted into a second product. The host cell includes Gram negative or Gram
20 positive host cells. In some embodiments, the host cell is an *Enterobacteriaceae* host cell that includes *Erwinia*, *Enterobacter*, *Gluconobacter*, *Acetobacter*, *Corynebacteria*, *Escherichia* or *Pantoea*. In other embodiments, the host cell is an that includes *Bacillus* and *Pseudomonas*.

In other embodiments, the host cell can be any bacteria that naturally or after proper
25 genetic modifications, is able to utilize one carbon source to maintain certain cell functions, for example, but not limited to, the generation of reducing power in the form of NAD, FADH₂ or NADPH, while another carbon source is converted into one or more product(s) of commercial interest.

In some embodiments, the uncoupling of the productive and catabolic pathways
30 allows the production of compounds generally derived from the catabolic pathway, wherein those products generally derived from the productive pathways are utilized to satisfy the metabolic demands of the host cell. In other embodiments, the uncoupling of the productive and catabolic pathway allows the production of compounds generally derived from the productive pathway, whereas those products derived from compounds present in the
35 catabolic pathway satisfy the metabolic demands of the host cell.

In some embodiments, the product includes those products generally derived from the catabolic pathway include those derived from fructose, the pentose pathway and the TCA cycle. In other embodiments, the product includes those generally derived from the productive pathway, e.g., an ascorbic acid intermediate including GA, KDG, DKG, KLG or
5 IA.

The invention also provides host cells comprising an productive pathway and a catabolic pathway, wherein said productive pathway and said catabolic pathways are uncoupled. In some embodiments, the host cells comprise a modification of the polynucleotide encoding an enzymatic activity such that such enzymatic activity is reduced
10 or inactivated. One such modification precludes the host cell from phosphorylating D-glucose at its 6th carbon and/or precludes a host cell from phosphorylating D-gluconic acid at its 6th carbon, wherein one or both of said polynucleotides is modified. In some embodiments, the enzymatic pathway that is
15 inactivated includes that of hexokinase, glucokinase; gluconokinase; phosphoenol pyruvate synthase (PEP); or phosphotransferase system (PTS).

The present invention also provides methods for producing host cells having modified levels of enzymatic activities. The present invention also provides novel nucleic acid and amino acid sequences for which lack enzymatic activity that phosphorylates D-
20 glucose at its 6th carbon and enzymatic activity that phosphorylates D-gluconate at its 6th carbon.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 provides a schematic representation of some of the metabolic routes involved in Glucose assimilation in *Pantoea citrea*. The enzymatic steps affected by the genetic
25 modifications described in the present invention, are indicated by an X. Boxes labeled with a T represent putative transporters.

Fig. 2. Some possible catabolic routes that can be used to channel glucose into cellular metabolism. The arrows represent at least one enzymatic step.

Fig.3. depicts products that can be obtained from indicated commercial routes. The majority of the carbon used to synthesize the compounds listed on the left side, can be
30 obtained from the catabolic pathway or TCA cycle. On the contrary, the compounds on the right, derive most of its carbon from the pentose pathway and/or from the oxidation of glucose into keto-acids.

Fig. 4 depicts a nucleic acid (SEQ ID NO:1) for a *Pantoea citrea* glucokinase
35

Fig. 5 depicts an amino acid (SEQ ID NO:2) sequence for a *Pantoea citrea* glucokinase.

Fig. 6 depicts a nucleic acid (SEQ ID NO:3) for a *Pantoea citrea* gluconokinase

Fig. 7 depicts an amino acid (SEQ ID NO:4) sequence for a *Pantoea citrea*
 5 gluconokinase.

Fig. 8 depicts amino acid (SEQ ID NO: 8-13) for the genes *glk 30*, *glk 31*, *gnt 1*, *gnt 2*, *pcgnt 3* and *pcgnt 4*.

Fig. 9 depicts D-glucose, D-gluconate and some of their derivatives. The standard numbering of the carbons on glucose is indicated by the numbers 1 and 6. 2-KDG=2-keto-
 10 D-gluconate; 2,5-DKG= 2,5-diketogluconate; 2KLG=2-keto-L-gulonate.

Fig. 10 depicts general strategy used to interrupt the gluconate kinase gene from *P. citrea*.

Fig. 11 depicts the oxidative pathway for the production of ascorbic acid. E1 stands for glucose dehydrogenase; E2 stands for gluconic acid dehydrogenase; E3 stands for 2-
 15 keto-D-gluconic acid dehydrogenase; and E4 stands for 2,5-diketo-D-gluconic acid reductase.

Fig. 12 depicts the net reactions during the fermentation of host cells capable of producing ascorbic acid intermediates.

Fig. 13 depicts carbon evolution rate (CER) and oxygen uptake rate (OUR) of a
 20 fermentation of a wild-type organism after exposure to glucose.

Fig. 14 depicts the CER and OUR of a fermentation with a single delete (glucokinase).

Fig. 15 depicts the CER and OUR of a fermentation with a single delete (gluconokinase).

25 Fig. 16 depicts the CER and OUR of a fermentation with a host cell having both glucokinase and gluconokinase deleted.

Fig. 17 is a schematic illustrating the interrelationships of various metabolic pathways (including the glycolytic pathway, TCA cycle, and pentose pathway) and the oxidative pathways. Glk = glucokinase; Gntk = gluconokinase; IdnO = 5-keto-D-gluconate 5-
 30 reductase; IdnD = L-Idonate 5-dehydrogenase; TKT = transketolase; TAL= transaldolase, 2KR = 2-keto reductase; 2,5DKGR= 2,5-diketogluconate reductase.

Figure 18 is a schematic illustrating the interrelationships of various central metabolic pathways and the modifications which would increase the production of ribose. The X indicate the enzymatic steps that would be modified to effect the desired increase in ribose
 35 yield.

- 8 -

Figure 19 is a schematic illustrating the interrelationships of various central metabolic pathways and the modifications which would increase the production of riboflavin. The X indicate the enzymatic steps that would be modified to effect the desired increase in ribose yield.

5 Figure 20 is a schematic illustrating the interrelationships of various central metabolic pathways and the modifications which would increase the production of nucleotides. The X indicate the enzymatic steps that would be modified to effect the desired increase in nucleotide yield.

Figure 21 is a schematic illustrating the interrelationships of various central metabolic pathways and the modifications which would increase the production of tartrate. The X indicate the enzymatic steps that would be modified to effect the desired increase in ribose production. IdnO= 5-keto-D-gluconate 5-reductase; IdnD = l-Idonate 5-dehydrogenase.

Figure 22 is a schematic illustrating the interrelationships of various central metabolic pathways and the modifications which would increase the production of gluconateribose. The X indicate the enzymatic steps that would be modified to effect the desired increase in gluconate production.

Figure 23 is a schematic illustrating the interrelationships of various central metabolic pathways and the modifications which would increase the production of erythorbic acid. The X indicate the enzymatic steps that would be modified to effect the desired increase in erythorbic acid production.

Figure 24 is a schematic illustrating the interrelationships of various central metabolic pathways and the modifications which would increase the production of 2,5-DKG. The X indicate the enzymatic or transport pathways that would be modified to effect the desired increase in 2,5-diketogluconate production.

25 Figure 25 is a schematic illustrating the pathway of dihydroxyacetone phosphate (DHAP) being converted to glycerol.

Figure 26 depicts the DNA Sequence of primers used to amplify by PCR the 2.9 kb DNA fragment that contains the glpK gene as described in Example 7.

Figure 27 describes the DNA sequence of the structural gene of the glycerol kinase from *P.citrea* as described in Example 7. The sequence of the HpaI site used to interrupt the gene is underlined.

Figure 28 depicts the protein sequence of the glycerol kinase from *P.citrea* as described in Example 7.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods for producing products comprising recombinant host cells that comprise an productive pathway and a catabolic pathway wherein said pathways are uncoupled in the host cell during part or all of said method, that
5 is wherein said pathways do not compete for initial carbon source, such as D-glucose or D-gluconic acid for example, or for cellular components, such as co-factor and ATP during part or all of said method. The invention encompasses methods wherein the productive and catabolic pathways are uncoupled via modification and/or regulation of enzymatic activities present in the productive and/or catabolic pathways.

10 The invention encompasses methods wherein the productive and catabolic pathway are coupled during part of said culturing, for example during the early part of said culturing where it is desirable to channel or direct host cell resources to building host cell biomass, and uncoupled during part of said culturing, for example, after host cell biomass has been produced or when it is desirable to channel or direct cell resources to production of product.
15 The invention encompasses methods comprising culturing recombinant host cells having a productive pathway and a catabolic pathway that are uncoupled during all of said culturing.

The invention encompasses methods wherein the productive and catabolic pathways are uncoupled at the stage of initial phosphorylation of the carbon source that is used by the cell, by modifying the genomic sequence that encodes such phosphorylation.

20 The uncoupling of the productive pathway and catabolic pathway encompasses inhibition of at least one enzymatic activity that phosphorylates the initial carbon source and/or any carbon metabolite in the productive and/or catabolic pathway. The uncoupling of the productive pathway and catabolic pathway encompasses inactivation of at least one enzymatic activity that phosphorylates the initial carbon source and/or any carbon
25 metabolite in the productive and/or catabolic pathway, such as by mutation in or deletion of part or all of the polynucleotide encoding an enzymatic activity that phosphorylates the initial carbon source and/or any carbon metabolite. The uncoupling of the productive pathway and catabolic pathway encompasses regulation of at least one enzymatic activity that phosphorylates the initial carbon source and/or any carbon metabolite in the productive
30 and/or catabolic pathway.

One advantage of the invention is that in host cells comprising uncoupled productive and catabolic pathways, the pathways are able to function simultaneously without one pathway creating a disadvantage for the other. In some embodiments disclosed herein, a host cell having a deletion of glucokinase and gluconokinase is cultured in the presence of
35 D-glucose. The D-glucose passes through the productive pathway without being diverted into the catabolic pathway, thereby increasing the amount of carbon substrate available for

- 10 -

conversion to the desired productive pathway generated product. Fructose, or other non-glucose carbon source, can be fed to the host cell and is used to satisfy the host cell's metabolic needs, freeing the D-glucose for use by the product pathway yielding the desired product. In this embodiment, the productive and catabolic pathways function simultaneously and non-competitively in the host cell.

Another advantage of the invention is that in host cells comprising uncoupled productive and catabolic pathways, either pathway can be used to provide for the metabolic needs of the host cell, freeing the other pathway to be used to produce products through that particular pathway. In some embodiments disclosed herein, a host cell having a deletion of the coupling enzymes enables the products of the productive pathway to satisfy the metabolic needs of the host cell, freeing the pathway usually associated with the generation of energy through the catabolic pathway to generate products. Thus fructose, or other non-glucose carbon source, can be fed to the host cell and is used to produce derivatives or desired products, while the host cell's metabolic needs are satisfied by conversion of productive pathway products to metabolic needs in the host cell.

In other embodiments, the ability of the host cell to use D-glucose, or a metabolite of D-glucose, such as D-gluconate, in the catabolic pathway, that is the ability of the host cell to phosphorylate D-glucose or D-gluconate at their respective 6th carbons, is regulated. Regulating the expression of the enzymatic activity allows a process wherein D-glucose or other carbon source is available to the catabolic pathway during the initial phase of culturing, where it is desirable to build cell biomass, and not available, that is not phosphorylated, at later stages of culturing where it may be desirable to maximize ATP production for use by the cell or where it may be desirable to feed a different carbon source to the cell for production of desired product.

In these embodiments, a particular advantage provided by the invention is the ability to make use of continuous fermentation processes for the production of products.

Another advantage provided by the invention is the uncoupling of the extracellular oxidation of a substrate from the metabolic pathways that use those oxidation products.

Another advantage provided by the invention is the increased efficiency in the production of products by the modified host cells as compared to wild-type host cells as measured directly by the increased conversion of substrate to end-product or indirectly as measured by O₂ consumption or CO₂ production.

A further advantage provided by the invention is the ability of the host cell to utilize two different carbon sources simultaneously for the production of products.

- 11 -

General Techniques

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, such as, *Molecular Cloning: A Laboratory Manual*, second edition (Sambrook *et al.*, 1989); *Current Protocols in Molecular Biology* (F.M. Ausubel *et al.*, eds., 1987 and annual updates); *Oligonucleotide Synthesis* (M.J. Gait, ed., 1984); and *PCR: The Polymerase Chain Reaction*, (Mullis *et al.*, eds., 1994). Manual of Industrial Microbiology and Biotechnology, Second Edition (A.L. Demain, *et al.*, eds. 1999)

Definitions

As used herein, the term "uncoupled" when referring to productive and catabolic pathways of a host cell means that the productive pathway of the host cell, including the substrates and products produced therein, have a reduced diversion of substrates to the catabolic pathway of the host cell. By reduced diversion, is meant that the yield of the wild type is less than the yield of the modified host cell.

As used herein, "productive pathway of a host cell" means that the host cell comprises at least one enzyme that converts a carbon source, such as, D-glucose and/or its metabolites to a desired product or intermediate. The productive pathway of the host cell includes but is not limited to the oxidative pathway of the host cell.

As used herein, "oxidative pathway of a host cell" means that the host cell comprises at least one oxidative enzyme that oxidizes a carbon source, such as, D-glucose and/or its metabolites. A "membrane" or "membrane bound" glucose productive pathway in a host cells refers to a host cell that oxidizes a carbon source such as, D-glucose and/or its metabolites, *via* at least one membrane bound productive enzymatic activity. In some embodiments, an oxidative pathway in a host cell comprises one enzymatic activity. In other embodiments, an oxidative pathway in a host cell comprises two or more enzymatic activities.

As used herein, "catabolic pathway of a host cell" means that the host cell comprises at least one enzymatic activity that generates ATP or NADPH, for example, by phosphorylating a carbon source, such as D-glucose and/or its metabolites. An "intracellular" catabolic pathway in a host cell means that the host cell comprises at least one such enzymatic activity in the host cell cytosol. In some embodiments, a catabolic pathway in a host cell comprises one enzymatic activity. In other embodiments, a catabolic pathway in a host cell comprises two or more enzymatic activities.

- 12 -

As used herein, the phrase "enzymatic activity which phosphorylates D-glucose at its 6th carbon" refers to an enzymatic activity that adds a phosphate to the 6th carbon of D-glucose and includes the enzymatic activities glucokinase (EC-2.7.1.2); and phosphotransferase system (PTS) (E.C.-2.7.1.69). As used herein, the phrase "enzymatic activity which phosphorylates D-gluconate at its 6th carbon" refers to an enzymatic activity that phosphorylates D-gluconate at its 6th carbon and includes the enzymatic activity gluconokinase (E.C.-2.7.1.12).

As used herein, "modifying" the levels of an enzymatic activity produced by a host cell or "modified levels" of an enzymatic activity of a host cell refers to controlling the levels of enzymatic activity produced during culturing, such that the levels are increased or decreased as desired. The desired change in the levels of enzymatic activity may be genetically engineered to take place in one or both enzymatic activities either simultaneously or sequentially, in any order. In order to control the levels of enzymatic activity, the host cell is genetically engineering such that nucleic acid encoding the enzymatic activity is transcriptionally or translationally controlled.

As used herein, the term "modified" when referring to nucleic acid or polynucleotide means that the nucleic acid has been altered in some way as compared to wild type nucleic acid, such as by mutation in; deletion of part or all of the nucleic acid; or by being operably linked to a transcriptional control region. As used herein the term "mutation" when referring to a nucleic acid refers to any alteration in a nucleic acid such that the product of that nucleic acid is partially or totally inactivated or eliminated. Examples of mutations include but are not limited to point mutations, frame shift mutations and deletions of part or all of a gene encoding an enzymatic activity, such as an enzymatic activity that transports the substrate across the cell membrane, e.g., phosphorylates D-glucose at its 6th carbon or an enzymatic activity that phosphorylates D-gluconate at its 6th carbon.

An "altered bacterial strain" according to the invention is a genetically engineered bacterial microorganism having an enhanced level of production over the level of production of the same end-product in a corresponding unaltered bacterial host strain grown under essentially the same growth conditions. An "unaltered bacterial strain" or host is a bacterial microorganism wherein the coding sequence of the diverting enzymatic pathway is not inactivated and remains enzymatically active. The enhanced level of production results from the inactivation of one or more chromosomal genes. In a first embodiment the enhanced level of expression results from the deletion of one or more chromosomal genes. In a second embodiment the enhanced level of expression results from the insertional inactivation of one or more chromosomal genes. Preferably the inactivated genes are selected from those encoding the enzymes whose inactivity is desired as described

- 13 -

elsewhere in this application. For example, in one embodiment one or more chromosomal genes is selected from the group consisting of *glk*, and *gntk*.

In certain embodiments, the altered bacterial strain may embody two inactivated genes, three inactivated genes, four inactivated genes, five inactivated genes, six
5 inactivated genes or more. The inactivated genes may be contiguous to one another or may be located in separate regions of the chromosome. An inactivated chromosomal gene may have a necessary function under certain conditions, but the gene is not necessary for microorganism strain viability under laboratory conditions. Preferred laboratory conditions include but are not limited to conditions such as growth in a fermentator, in a shake plate, in
10 plate media or the like.

As used herein, the term "inactivation" or "inactivating" when referring to an enzymatic activity means that the activity has been eliminated by any means including a mutation in or deletion of part or all of the nucleic acid encoding the enzymatic activity. The term "inactivation" or "inactivating" includes any method that prevents the functional
15 expression of one or more of the desired chromosomal genes, wherein the gene or gene product is unable to exert its known function. The desired chromosomal genes will depend upon the enzymatic activity that is intended to be inactivated. For example the inactivation of glucokinase and/or gluconokinase activity can be effected by inactivating the *glk* and/or *gntk* chromosomal genes coding regions. Inactivation may include such methods as
20 deletions, mutations, interruptions or insertions in the nucleic acid gene sequence. In one embodiment, the expression product of an inactivated gene may be a truncated protein as long as the truncated protein does not show the biological activity of the unaltered coding region. In an altered bacterial strain according to the invention, the inactivation of the one or more genes will preferably be a stable and non-reverting inactivation.

25 In a preferred embodiment, preferably a gene is deleted by homologous recombination. For example, as shown in Figure 9, when *glk* is the gene to be deleted, a chloramphenicol resistance gene is cloned into a unique restriction site found in the glucokinase gene. The Cm^{R} gene is inserted into the structural coding region of the gene at the Pst I site. Modification is then transferred to the chromosome of a *P. citrea* *glkA*- by
30 homologous recombination using a non-replication R6K vector. The Cm^{R} gene is subsequently removed from the *glk* coding region leaving an interrupting spacer in the coding region, inactivating the coding region. In another embodiment, the Cm^{R} gene is inserted into the coding region in exchange for portions of the coding region. Subsequent removal of the Cm^{R} gene without concomitant return of the exchanged out portion of the
35 coding region results in an effective deletion of a portion of the coding region, inactivating such region.

A deletion of a gene as used herein may include deletion of the entire coding sequence, deletion of part of the coding sequence, or deletion of the coding sequence including flanking regions. The deletion may be partial as long as the sequences left in the chromosome are too short for biological activity of the gene. The flanking regions of the coding sequence may include from about 1bp to about 500 bp at the 5' and 3' ends. The flanking region may be larger than 500 bp but will preferably not include other genes in the region which may be inactivated or deleted according to the invention. The end result is that the deleted gene is effectively non-functional.

In another preferred embodiment, inactivation is by insertion. For example when *glk* is the gene to be inactivated, a DNA construct will comprise an incoming sequence having the *glk* gene interrupted by a selective marker. The selective marker will be flanked on each side by sections of the *glk* coding sequence. The DNA construct aligns with essentially identical sequences of the *glk* gene in the host chromosome and in a double crossover event the *glk* gene is inactivated by the insertion of the selective marker.

In another embodiment, inactivation is by insertion in a single crossover event with a plasmid as the vector. For example, a *glk* chromosomal gene is aligned with a plasmid comprising the gene or part of the gene coding sequence and a selective marker. The selective marker may be located within the gene coding sequence or on a part of the plasmid separate from the gene. The vector is integrated into the *Bacillus* chromosome, and the gene is inactivated by the insertion of the vector in the coding sequence.

Inactivation may also occur by a mutation of the gene. Methods of mutating genes are well known in the art and include but are not limited to chemical mutagenesis, site-directed mutation, generation of random mutations, and gapped-duplex approaches. (USP 4,760,025; Moring et al., *Biotech.* 2:646 (1984); and Kramer et al., *Nucleic Acids Res.* 12:9441 (1984)).

Inactivation may also occur by applying the above described inactivation methods to the respective promoter regions of the desired genomic region.

"Under transcriptional control" or "transcriptionally controlled" are terms well understood in the art that indicate that transcription of a polynucleotide sequence, usually a DNA sequence, depends on its being operably (operatively) linked to an element which contributes to the initiation of, or promotes, transcription. "Operably linked" refers to a juxtaposition wherein the elements are in an arrangement allowing them to function.

As used herein, the term "regulatable promoter" refers to a promoter element which activity or function can be modulated. This modulation can be accomplished in many different ways, most commonly by the interaction of protein(s) that interfere or increase the ability of the RNA polymerase enzyme to initiate transcription.

- 15 -

"Under translational control" well understood in the art that indicates a regulatory process that occurs after the messenger RNA has been formed.

As used herein, the term "batch" describes a batch cell culture to which substrate, in either solid or concentrated liquid form, is added initially at the start of the run. A batch culture is initiated by inoculating cells to the medium, but, in contrast to a fed-batch culture, there is no subsequent inflow of nutrients, such as by way of a concentrated nutrient feed. In contrast to a continuous culture, in a batch cell culture, there is no systematic addition or systematic removal of culture fluid or cells from a culture. There is no ability to subsequently add various analytes to the culture medium, since the concentrations of nutrients and metabolites in culture medium are dependent upon the initial concentrations within the batch and the subsequent alteration of the composition of the nutrient feed due to the act of fermentation.

As used herein, the term "fed-batch" describes a batch cell culture to which substrate, in either solid or concentrated liquid form, is added either periodically or continuously during the run. Just as in a batch culture, a fed-batch culture is initiated by inoculating cells to the medium, but, in contrast to a batch culture, there is a subsequent inflow of nutrients, such as by way of a concentrated nutrient feed. In contrast to a continuous culture there is no systematic removal of culture fluid or cells from a fed-batch culture is advantageous in applications that involve monitoring and manipulating the levels of various analytes in the culture medium, since the concentrations of nutrients and metabolites in culture medium can be readily controlled or affected by altering the composition of the nutrient feed. The nutrient feed delivered to a fed-batch culture is typically a concentrated nutrient solution containing an energy source, e.g., carbohydrates; optionally, the concentrated nutrient solution delivered to a fed-batch culture can contain amino acids, lipid precursors and/or salts. In a fed-batch culture, this nutrient feed is typically rather concentrated to minimize the increase in culture volume while supplying sufficient nutrients for continued cell growth.

The term "continuous cell culture" or, simply, "continuous culture" is used herein to describe a culture characterized by both a continuous inflow of a liquid nutrient feed and a continuous liquid outflow. The nutrient feed may, but need not, be a concentrated nutrient feed. Continuously supplying a nutrient solution at about the same rate that cells are washed out of the reactor by spent medium allows maintenance of a culture in a condition of stable multiplication and growth. In a type of bioreactor known as a chemostat, the cell culture is continuously fed fresh nutrient medium, and spent medium, cells and excreted cell product are continuously drawn off. Alternatively, a continuous culture may constitute a "perfusion culture," in which case the liquid outflow contains culture medium that is

substantially free of cells, or substantially lower cell concentration than that in the bioreactor. In a perfusion culture, cells can be retained by, for example, filtration, centrifugation, or sedimentation.

“Culturing” as used herein refers to fermentive bioconversion of a carbon substrate to the desired end-product within a reactor vessel. Bioconversion as used herein refers to the use of contacting a microorganism with the carbon substrate to convert the carbon substrate to the desired end-product .

As used herein, “Oxygen Uptake Rate or “OUR” refers to the determination of the specific consumption of oxygen within the reactor vessel. Oxygen consumption can be determined using various on-line measurements. In one example, the OUR (mmol/(liter*hour)) is determined by the following formula: ((Airflow (standing liters per minute) / Fermentation weight (weight of the fermentation broth in kilograms)) X supply O₂ X broth density X (a constant to correct for airflow calibration at 21.1 C instead of standard 20.0 C)) minus ((airflow /fermentation weight] x [offgas O₂/offgas N₂] X supply N₂ X broth density X constant).

As used herein, “carbon evolution rate or “CER” refers to the determination of how much CO₂ is produced within the reactor vessel during fermentation. Usually, since no CO₂ is initially or subsequently provided to the reaction vessel, any CO₂ is assumed to be produced by the fermentation process occurring within the reaction vessel. “Off-gas CO₂” refers to the amount of CO₂ measured within the reactor vessel, usually by mass spectroscopic methods known in the art.

As used herein, “yield” refers to the amount of product divided by the amount of substrate. The yield can be expressed as a weight % (product gm/substrate gm) or as moles of product/moles of substrate. For example, the amount of the substrate, e.g., glucose can be determined by the feed rate and the concentration of the added glucose. The amount of products present can be determined by various spectrophotometric or analytic methodologies. One such methodology is high performance liquid chromatography (HPLC). An increased yield refers to an increased yield as compared to the yield of a conversion using the wild-type organism, for example an increase of 10%, 20%, or 30% over the yield of the wild-type.

The phrase “oxidative enzyme” as used herein refers to an enzyme or enzyme system which can catalyze conversion of a substrate of a given oxidation state to a product of a higher oxidation state than substrate. The phrase “reducing enzyme” refers to an enzyme or enzyme system which can catalyze conversion of a substrate of a given oxidation state to a product of a lower oxidation state than substrate. In one illustrative example disclosed herein, productive enzymes associated with the biocatalysis of D-glucose

- 17 -

or its metabolites in a *Pantoea* cell which has been engineered to produce ASA intermediates, include among others D-glucose dehydrogenase, D-gluconate dehydrogenase and 2-keto-D-gluconate dehydrogenase. In another illustrative embodiment disclosed herein, reducing enzymes associated with the biocatalysis of D-glucose or its metabolites in a *Pantoea* cell which has been engineered to produce ASA intermediates, as described herein, include among others 2,5-diketo-D-gluconate reductase, 2-keto reductase and 5-keto reductase. Such enzymes include those produced naturally by the host strain or those introduced via recombinant means.

As used herein, the term carbon source encompasses suitable carbon sources ordinarily used by microorganisms, such as 6 carbon sugars, including but not limited to glucose, gulose, sorbose, fructose, idose, galactose and mannose all in either D or L form, or a combination of 6 carbon sugars, such as glucose and fructose, and/or 6 carbon sugar acids including but not limited to 2-keto-L-gulonic acid, idonic acid, gluconic acid, 6-phosphogluconate, 2-keto-D-gluconic acid, 5-keto-D-gluconic acid, 2-ketogluconatephosphate, 2, 5-diketo-L-gulonic acid, 2,3-L-diketogulonic acid, dehydroascorbic acid, erythroascorbic acid, erythorbic acid and D-mannonic acid or the enzymatic derivatives of such.

The following definitions apply as used herein to D-glucose or glucose (G); D-gluconate or gluconate (GA); 2-keto-D-gluconate (2KDG); 2,5-diketo-D-gluconate (2,5DKG or DKG); 2-keto-L-gulonic acid (2KLG, or KLG); L-idonic acid (IA); erythorbic acid (EA); ascorbic acid (ASA); glucose dehydrogenase (GDH); gluconic acid dehydrogenase (GADH); 2,5-diketo-D-gluconate reductase (DKGR); 2-keto-D-gluconate reductase (KDGDH); D-ribose (R); 2-keto reductase (2KR or KR); and 5-keto reductase (5KR or KR).

"Carbon metabolite" as used herein refers to a compound that is utilized in the catabolic pathway to generate ATP, NADPH and/or is phosphorylated for transport into the cell.

"Allowing the production of an ascorbic acid intermediate from the carbon source, wherein the production of said ascorbic acid intermediate is enhanced compared to the production of the ascorbic acid intermediate in the unaltered bacterial host strain" means contacting the substrate, e.g. carbon source, with the altered bacterial strain to produce the desired end-product. The inventors discovered that by altering certain enzymatic activities by inactivating genomic expression, the microorganism demonstrated enhanced end-product production.

"Desired end-product" as used herein refers to the desired compound to which the carbon substrate is bioconverted into. The desired end-product may be the actual

compound sought or an intermediate along another pathway. Exemplary desired end-products are listed on the right side of Figure 3.

As used herein, the term "bacteria" refers to any group of microscopic organisms that are prokaryotic, i.e., that lack a membrane-bound nucleus and organelles. All bacteria are
5 surrounded by a lipid membrane that regulates the flow of materials in and out of the cell. A rigid cell wall completely surrounds the bacterium and lies outside the membrane. There are many different types of bacteria, some of which include, and are not limited to those strains within the families of Enterobacteriaceae, Bacillus, Streptomyces, Pseudomonas, and Erwinia.

10 As used herein, the family "*Enterobacteriaceae*" refers to bacterial strains having the general characteristics of being Gram negative and being facultatively anaerobic. For the production of ASA intermediates, preferred *Enterobacteriaceae* strains are those that are able to produce 2,5-diketo-D-gluconic acid from D-glucose or carbon sources which can be converted to D-glucose by the strain. Included in the family of *Enterobacteriaceae* which are
15 able to produce 2,5-diketo-D-gluconic acid from D-glucose solutions are the genus *Erwinia*, *Enterobacter*, *Gluconobacter* and *Pantoea*, for example. Intermediates in the microbial pathway from carbon source to ASA, include but are not limited to GA, KDG, DKG, DKG, KLG and IA. In the present invention, a preferred *Enterobacteriaceae* fermentation strain for the production of ASA intermediates is a *Pantoea* species and in particular, *Pantoea citrea*.

20 As used herein the family "Bacillus" refers to rod-shaped bacterial strains having the general characteristics of being gram positive, capable of producing spores under certain environmental conditions. Other *Enterobacteriaceae* strains that produce ASA intermediates include, but are not limited to, *E. coli* and *Gluconobacter*.

As used herein, the term "recombinant" refers to a host cell that has a modification of
25 its genome, eg as by the additional of nucleic acid not naturally occurring in the organism or by a modification of nucleic acid naturally occurring in the host cell and includes host cells having additional copies of endogenous nucleic acid introduced via recombinant means. The term "heterologous" as used herein refers to nucleic acid or amino acid sequences not naturally occurring in the host cell. As used herein, the term "endogenous" refers to a
30 nucleic acid naturally occurring in the host.

The terms "isolated" or "purified" as used herein refer to an enzyme, or nucleic acid or protein or peptide or co-factor that is removed from at least one component with which it is naturally associated. In the present invention, an isolated nucleic acid can include a vector comprising the nucleic acid.

35 It is well understood in the art that the acidic derivatives of saccharides, may exist in a variety of ionization states depending upon their surrounding media, if in solution, or out of

solution from which they are prepared if in solid form. The use of a term, such as, for example, idonic acid, to designate such molecules is intended to include all ionization states of the organic molecule referred to. Thus, for example, "idonic acid", its cyclized form "idonolactone", and "idonate" refer to the same organic moiety, and are not intended to specify particular ionization states or chemical forms.

As used herein, the term "vector" refers to a polynucleotide construct designed for transduction/transfection of one or more cell types including for example, "cloning vectors" which are designed for isolation, propagation and replication of inserted nucleotides or "expression vectors" which are designed for expression of a nucleotide sequence in a host cell, such as a *Pantoea citrea* or *E. coli* host cell.

The terms "polynucleotide" and "nucleic acid", used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. These terms include a single-, double- or triple-stranded DNA, genomic DNA, cDNA, RNA, DNA-RNA hybrid, or a polymer comprising purine and pyrimidine bases, or other natural, chemically, biochemically modified, non-natural or derivatized nucleotide bases. The backbone of the polynucleotide can comprise sugars and phosphate groups (as may typically be found in RNA or DNA), or modified or substituted sugar or phosphate groups. Alternatively, the backbone of the polynucleotide can comprise a polymer of synthetic subunits such as phosphoramidates and thus can be a oligodeoxynucleoside phosphoramidate (P-NH₂) or a mixed phosphoramidate- phosphodiester oligomer. Peyrottes et al. (1996) *Nucleic Acids Res.* 24: 1841-8; Chaturvedi et al. (1996) *Nucleic Acids Res.* 24: 2318-23; Schultz et al. (1996) *Nucleic Acids Res.* 24: 2966-73. A phosphorothioate linkage can be used in place of a phosphodiester linkage. Braun et al. (1988) *J. Immunol.* 141: 2084-9; Latimer et al. (1995) *Molec. Immunol.* 32: 1057-1064. In addition, a double-stranded polynucleotide can be obtained from the single stranded polynucleotide product of chemical synthesis either by synthesizing the complementary strand and annealing the strands under appropriate conditions, or by synthesizing the complementary strand de novo using a DNA polymerase with an appropriate primer. Reference to a polynucleotide sequence (such as referring to a SEQ ID NO) also includes the complement sequence.

The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars and linking groups such as fluororibose and thioate,

- 20 -

and nucleotide branches. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. Other types of modifications included in this definition are caps, substitution of one or more of the naturally occurring nucleotides
 5 with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides, or a solid support. Preferably, the polynucleotide is DNA. As used herein, "DNA" includes not only bases A, T, C, and G, but also includes any of their analogs or modified forms of these bases, such as methylated nucleotides, internucleotide modifications such as uncharged linkages and thioates, use of
 10 sugar analogs, and modified and/or alternative backbone structures, such as polyamides.

A polynucleotide or polynucleotide region has a certain percentage (for example, 80%, 85%, 90%, 95%, 97% or 99%) of "sequence identity" to another sequence means that, when aligned, that percentage of bases are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using
 15 software programs known in the art, for example those described in *Current Protocols in Molecular Biology* (F.M. Ausubel et al., eds., 1987) Supplement 30, section 7.7.18. A preferred alignment program is ALIGN Plus (Scientific and Educational Software, Pennsylvania), preferably using default parameters, which are as follows: mismatch = 2; open gap = 0; extend gap = 2.

20 A polynucleotide sequence that is "depicted in" a SEQ ID NO means that the sequence is present as an identical contiguous sequence in the SEQ ID NO. The term encompasses portions, or regions of the SEQ ID NO as well as the entire sequence contained within the SEQ ID NO.

"Expression" includes transcription and/or translation.

25 As used herein, the term "comprising" and its cognates are used in their inclusive sense; that is, equivalent to the term "including" and its corresponding cognates.

"A," "an" and "the" include plural references unless the context clearly dictates otherwise.

30

Productive and catabolic pathways of host cells

Figures 2 and 3 describe some of the products of metabolism that can be obtained from some of the metabolic routes. The majority of the products on the left side of figure 3 (Glucose-6-phosphate, glucose-1-phosphate; fructose-6-phosphate, mannose-6-phosphate,
 35 dihydroacetone-phosphate; dihydroacetone; glycerol; 1,2-propanediol; 1,3 propanediol; lactic acid; succinic acid; oxalic acid; citric acid; fumaric acid; malic acid; amino acids;

- 21 -

glycogen; trehalose; and UDP-glucose) can be obtained from the catabolic or TCA cycle. On the contrary, the compounds on the right, desired end-products for the purposes of this invention (gluconic acid, 2-keto-D-gluconic acid, 2,5-di-keto-gluconate; erythorbic acid; 5-keto-D-gluconate; tartaric acid; D-ribose; riboflavin; deoxyribonucleotides; aromatic amino acids, aromatic compounds [e.g. P-hydroxybenzoic acid; quinines; catechols; indoles; indigo; gallic acid; pyrogallol; melanin, adipic acid, p-aminobenzoic acid]; pyridoxine and aspartame) derive most of its carbon from the pentose pathway and/or from the oxidation of glucose into keto acid. In many cases, these products are not natural products of the metabolism of a particular cell, but they can be produced by adding or removing certain enzymatic functions.

Generally, those products on the left side of Figure 3 are used to maintain the catabolic needs of the host cell. By uncoupling the interaction between those compounds on the left with those on the right, the metabolic requirements of the host cell are satisfied by the products generated on one side, enabling more carbon substrate to be converted into the desired productive product. In one embodiment, the uncoupling of the productive pathways from the catabolic pathways increase the yield of compounds produced on the right side. In another embodiment, it is contemplated using the products generated by the productive pathways to maintain the metabolic requirements of the host cell would enable those reactions in the catabolic pathways to be utilized to increase the yield of products derived from those products within the catabolic pathway, e.g. 1,3-propanediol, DHAP, lactic acid.

The invention also includes functionally-preserved variants of the modified nucleic acid sequences disclosed herein, which include nucleic acid substitutions, additions, and/or deletions. In one embodiment, the variants include modified sequences encoding glucokinase and gluconokinase, which inactivates the enzymatic pathway converting glucose to glucose-6-phosphate and gluconate to gluconate-6-phosphate, uncoupling the productive pathways from the catabolic pathways, reducing the amount of carbon substrate diverted to the catabolic pathway and increasing the amount of carbon substrate available for conversion into the desired product, e.g. 2-KLG. Genetic modifications are used to eliminate the communication between the catabolic functions and the enzymatic reactions that are required to synthesize a desired product. While various modifications are described in this application (see Figs. 17-24), the inventors contemplate that other enzymatic steps could be modified to achieve the same uncoupling oxidative, catabolic pathway uncoupling.

Esters of phosphoric acid are encountered with trioses, tetroses, pentoses, hexoses and heptoses. The phosphorylation of all sugars is the initial step in their metabolism. Thus

- 22 -

glucose can be phosphorylated to glucose 6-phosphate. All cells that can metabolize glucose contain some form of a hexokinase which catalyze the reaction



5

Figure 9 depicts D-glucose and illustrates the "6th carbon". Exemplary hexokinases include hexokinase (Frohlich, et al., 1985, Gene 36:105-111) and glucokinase (Fukuda, et al., 1983, J. Bacteriol. 156:922-925). The DNA sequence of the glucokinase structural gene from *P. citrea* is shown in Fig. 4. The recognition site for the restriction enzymes NcoI (CCATGG) and SnaBI (TACGTA) are highlighted. Fig. 5 depicts the protein sequence of the glucokinase gene from *P. citrea*. Most hexokinases are somewhat nonspecific, showing some ability to catalyze formation of 6-phosphate esters of mannose, fructose, and galactose. In addition, other hexose derivatives may also be phosphorylated by a hexokinase. Gluconate (Fig. 3), for example, may also be phosphorylated by a kinase, specifically gluconokinase (citation). The sequence for the gluconokinase structural gene from *P. citrea* is depicted in Fig. 6. The recognition site for the restriction enzyme Pst I (CTGCAG) is highlighted. The protein sequence for the gluconokinase gene from *P. citrea* is depicted in Fig. 7 (SEQ ID NO 4). The some of the genes for glucokinase And gluconokinase (glk, gntk, etc.) are shown in Fig. 8.

Fig. 17 shows the interrelationships between the catabolic pathways and the productive (oxidative) pathway. Glucose can enter the catabolic pathways through the glycolytic pathway by the phosphorylation of glucose to glucose-6-phosphate by glucokinase (Glk); and through the pentose pathway by the phosphorylation of gluconate to gluconate-6-phosphate by glucono kinase (Gntk). Inactivation or modifying the levels of glucokinase and gluconokinase by modifying the nucleic acid or polypeptide encoding the same (*glk* or *gntk*), results in the increased yield of the desired product, e.g. an ascorbic acid intermediate. As used herein, ascorbic acid intermediate includes those sugar acids produced within the oxidative pathway from glucose to 2KLG, including, but not limited to gluconate, 2-KGD, 2,5-DKG, 2-KLG, and 5-DKG.

In another embodiment, the catabolic pathway is uncoupled from the productive pathway to increase the production of ribose. As shown in Figure 18, glucose can enter the catabolic pathway through the glycolytic pathway, for example through glucose-6-phosphate, fructose-6-phosphate, and/or glyceraldehydes-3-phosphate. Inactivation or modifying the levels of glucokinase, gluconokinase, ribulose-5-phosphate epimerase, transketolase and transaldolase, by modifying the nucleic acid or polypeptide encoding the same, results in the increased yield of the desired product, e.g. ribose.

In another embodiment, the catabolic pathway is uncoupled from the productive pathway to increase the production of riboflavin. As shown in Figure 19, glucose can enter the catabolic pathway through the glycolytic pathway, for example through glucose-6-phosphate, and the pentose pathway. Inactivation or modifying the levels of glucokinase, ribulose-5-phosphate epimerase and ribose-5-phosphate isomerase, by modifying the nucleic acid or polypeptide encoding the same, results in the increased yield of the desired product, e.g. riboflavin.

In another embodiment, the catabolic pathway is uncoupled from the productive pathway to increase the production of nucleotides. As shown in Figure 20, glucose can enter the catabolic pathway through the glycolytic pathway, for example through glucose-6-phosphate, fructose-6-phosphate, and/or glyceraldehydes-3-phosphate. Inactivation or modifying the levels of glucokinase, ribulose-5-phosphate epimerase, transaldolase and transketolase, by modifying the nucleic acid or polypeptide encoding the same, results in the increased yield of the desired product, e.g. nucleotides.

In another embodiment, the catabolic pathway is uncoupled from the productive pathway to increase the production of 5-KDG and/or tartrate. As shown in Figure 21, glucose can enter the catabolic pathway through the glycolytic pathway, for example through glucose-6-phosphate, the pentose pathway through gluconate-6-phosphate, and other ascorbic acid by-products, such as idonate and 2-KLG. Inactivation or modifying the levels of glucokinase, gluconokinase, 2,5-DKG reductase, and Idonate dehydrogenase, by modifying the nucleic acid or polypeptide encoding the same, results in the increased yield of the desired product, e.g. 5-DKG and/or tartrate.

In another embodiment, the catabolic pathway is uncoupled from the productive pathway to increase the production of gluconate. As shown in Figure 22, glucose can enter the catabolic pathway through the glycolytic pathway, for example through glucose-6-phosphate and the pentose pathway, through gluconate-6-phosphate. Inactivation or modifying the levels of glucokinase, gluconokinase, and glyceraldehyde hydrogenase, by modifying the nucleic acid or polypeptide encoding the same, results in the increased yield of the desired product, e.g. gluconate.

In another embodiment, the catabolic pathway is uncoupled from the productive pathway to increase the production of erythorbic acid. As shown in Figure 23, glucose can enter the catabolic pathway through the glycolytic pathway, for example through glucose-6-phosphate; the pentose pathway, through gluconate-6-phosphate; and by an enzymatic transport system transporting 2-KDG and 2,5-KDG into the cytoplasm. Inactivation or modifying the levels of glucokinase, gluconokinase, glyceraldehyde hydrogenase and the

transport system of 2-KDG into the cytoplasm, by modifying the nucleic acid or polypeptide encoding the same, results in the increased yield of the desired product, e.g. erythoric acid.

In another embodiment, the catabolic pathway is uncoupled from the productive pathway to increase the production of 2,5-DKG. As shown in Figure 24, glucose can enter the
5 catabolic pathway through the glycolytic pathway, for example through glucose-6-phosphate; the pentose pathway, through gluconate-6-phosphate; and by an enzymatic transport system transporting 2-KDG and 2,5-KDG into the cytoplasm. Inactivation or modifying the levels of glucokinase, gluconokinase, and 2-KDG hydrogenase; and the enzymatic transport system for 2-KDG, by modifying the nucleic acid or polypeptide
10 encoding the same, results in the increased yield of the desired product, e.g. 2,5-DKG. Wherein the inventors have provided in some instances amino acid sequences and nucleotide sequences for genomic coding regions and/or protein (enzymes) in question, those skilled in the art will recognize that the genomic loci not specifically provided herein are readily ascertainable by construction of probes or hybridizing sequences incorporating
15 already known sequences and a homology alignment of (for example BLAST), in one embodiment, at least 30% or at least 50%, another embodiment, of the known coding region sequence. In another embodiment, a homology alignment of at least 60%, 70%, 75%, 80%, 90%, 95%, 97% or even 98% of the known sequence will identify the coding region to which the inactivation techniques described elsewhere are applied to effect the desired. Another
20 methodology to determine the coding regions for the particular enzyme known to those of skill in the art is to obtain several known sequences, align the sequences to determine the conserved region, then design degenerate oligoprimers followed by PCR amplification of the connecting regions between the framing residues to ascertain the desired genomic region.

The availability of recombinant techniques to effect expression of enzymes in foreign
25 hosts permits the achievement of the aspect of the invention which envisions production of a desired end-product, e.g., riboflavin, tartrate, 5-KDG, ribose, nucleotides, gluconate, erythorbic acid, 2,5-DKG, other ascorbic acid intermediates or other desired products with a reduced amount of carbon substrate diverted to catabolic pathways from a readily available carbon substrate. This method has considerable advantage over presently used methods in
30 characterized by a reduction in the amount of substrate converted to the catabolic pathway and thus unavailable for conversion to the desired oxidative end-product, e.g., an ascorbic acid intermediate. This results in increased fermentative efficiency and increased yield over fermentations with wild type organisms. Certain wild type organisms may produce ascorbic acid intermediates, e.g., 2-KLG, however the level produced may not be sufficient to be
35 economically practical. It has been observed that wild type *Pantoea citrea* has its own cytoplasmic glucokinase and gluconokinase enabling the organism to convert glucose to

phosphorylated derivatives for use in its central metabolic pathways and the production of which, necessarily consume energy, ATP and causes that more carbon goes to non-2-KLG producing pathways. Under the same controlled conditions and using the method of this invention, described below, in two interruption plasmid described elsewhere in this application the glucokinase and gluconokinase genes can be deleted from the *P. citrea* genome, enabling the modified *P. citrea* to produce increased DKG from glucose at a level increased over the wild-type, e.g. level of 63% yield to about 97-98% yield. [see Example 6].

Other variants include, but are not limited to, inactivations of the *gap* gene to increase production of dihydroacetone-phosphate, DHAP; erythorbic acid; and tartic acid.

The variants of the sequences disclosed herein may be 80%, 85%, 90%, 95%, 98%, 99% or more identical, as measured by, for example, ALIGN Plus (Scientific and Educational Software, Pennsylvania), preferably using default parameters, which are as follows: mismatch = 2; open gap = 0; extend gap = 2 to any of the enzymatic sequences disclosed herein. Variants of glucokinase and gluconokinase sequences may also hybridize at high stringency, that is at 68°C and 0.1X SSC, to the glucokinase and gluconokinase sequences disclosed herein.

In terms of hybridization conditions, the higher the sequence identity required, the more stringent are the hybridization conditions if such sequences are determined by their ability to hybridize to a sequence of SEQ ID NO:1 or SEQ ID NO:3. Accordingly, the invention also includes polynucleotides that are able to hybridize to a sequence comprising at least about 15 contiguous nucleotides (or more, such as about 25, 35, 50, 75 or 100 contiguous nucleotides) of SEQ ID NO:1 or SEQ ID NO:3. The hybridization conditions would be stringent, i.e., 80°C (or higher temperature) and 6M SSC (or less concentrated SSC). Another set of stringent hybridization conditions is 68°C and 0.1 X SSC. For discussion regarding hybridization reactions, see below.

Hybridization reactions can be performed under conditions of different "stringency". Conditions that increase stringency of a hybridization reaction of widely known and published in the art. See, for example, Sambrook et al. (1989) at page 7.52. Examples of relevant conditions include (in order of increasing stringency): incubation temperatures of 25°C, 37°C, 50°C and 68°C; buffer concentrations of 10 X SSC, 6 X SSC, 1 X SSC, 0.1 X SSC (where SSC is 0.15 M NaCl and 15 mM citrate buffer) and their equivalents using other buffer systems; formamide concentrations of 0%, 25%, 50%, and 75%; incubation times from 5 minutes to 24 hours; 1, 2, or more washing steps; wash incubation times of 1, 2, or 15 minutes; and wash solutions of 6 X SSC, 1 X SSC, 0.1 X SSC, or deionized water. An exemplary set of stringent hybridization conditions is 68°C and 0.1 X SSC.

- 26 -

" T_m " is the temperature in degrees Celcius at which 50% of a polynucleotide duplex made of complementary strands hydrogen bonded in anti-parallel direction by Watson-Crick base pairing dissociates into single strands under conditions of the experiment. T_m may be predicted according to a standard formula, such as:

$$T_m = 81.5 + 16.6 \log[X^+] + 0.41 (\%G/C) - 0.61 (\%F) - 600/L$$

where $[X^+]$ is the cation concentration (usually sodium ion, Na^+) in mol/L; (%G/C) is the number of G and C residues as a percentage of total residues in the duplex; (%F) is the percent formamide in solution (wt/vol); and L is the number of nucleotides in each strand of the duplex.

I. Production of ASA intermediates

The present invention also provides methods for the production of ascorbic acid intermediates in host cells. The present invention encompasses methods wherein the levels of an enzymatic activity couple the catabolic and productive pathways, e.g., those which phosphorylate D-glucose at its 6th carbon and/or which phosphorylates D-gluconate at its 6th carbon are decreased during part or all of the culturing. The present invention encompasses methods wherein the levels of an enzymatic activity which phosphorylates D-glucose at its 6th carbon and/or the levels of an enzymatic activity which phosphorylates D-gluconate at its 6th carbon are increased during part or all of the culturing. The present invention also encompasses a method wherein the levels of an enzymatic activity which phosphorylates D-glucose at its 6th carbon and/or the levels of an enzymatic activity which phosphorylates D-gluconate at its 6th carbon are not modified or are increased at the beginning of the culturing to facilitate growth, that is, to produce cell biomass, and decreased during the later phases of culturing to facilitate desired product accumulation.

The ASA intermediate may be further converted to a desired end product such as ASA or erythorbate. For the production of ASA intermediates, any host cell which is capable of converting a carbon source to DKG can be used. Preferred strains of the family *Enterobacteriaceae* are those that produce 2,5-diketo-D-gluconic acid from D-glucose solutions, including *Pantoea*, are described in Kageyama et al. (1992) *International Journal of Systematic Bacteriology* vol. 42, p. 203-210. In a preferred embodiment, the host cell is *Pantoea citrea* having a deletion of part or all of a polynucleotide that encodes an endogenous glucokinase (encoded by nucleic acid as depicted in SEQ ID NO:1) and a deletion of part or all of a polynucleotide that encodes an endogenous gluconokinase (encoded by nucleic acid as depicted in SEQ ID NO:3).

The production of ASA intermediates can proceed in a fermentative environment, that is, in an *in vivo* environment, or a non-fermentative environment, that is, in an *in vitro* environment; or combined *in vivo/in vitro* environments. In the methods which are further described *infra*, the host cell or the *in vitro* environment further comprise a heterologous
5 DKG reductase which catalyses the conversion of DKG to KLG.

A. In vivo biocatalytic environment

The present invention encompasses the use of host cells comprising a modification in a polynucleotide encoding an endogenous enzymatic activity that phosphorylates D-
10 glucose at its 6th carbon and/or a modification in a polynucleotide encoding an enzymatic activity that phosphorylates D-gluconate at its 6th carbon in the *in vivo* production of ASA intermediates. Biocatalysis begins with culturing the host cell in an environment with a suitable carbon source ordinarily used by *Enterobacteriaceae* strains, such as a 6 carbon sugar, for example, glucose, or a 6 carbon sugar acid, or combinations of 6 carbon sugars
15 and/or 6 carbon sugar acids. Other carbon sources include, but are not limited to galactose, lactose, fructose, or the enzymatic derivatives of such. In addition to an appropriate carbon source, fermentation media must contain suitable minerals, salts, cofactors, buffers and other components, known to those of skill in the art for the growth of cultures and promotion of the enzymatic pathway necessary for production of desired end-products.

20 In one illustrative *in vivo Pantoea* pathway, D-glucose undergoes a series of membrane productive steps through enzymatic conversions, which may include the enzymes D-glucose dehydrogenase, D-gluconate dehydrogenase and 2-keto-D-gluconate dehydrogenase to give intermediates which may include, but are not limited to GA, KDG, and DKG, see Figure 1. These intermediates undergo a series of intracellular reducing
25 steps through enzymatic conversions, which may include the enzymes 2,5-diketo-D-gluconate reductase (DKGR), 2-keto reductase (2-KR) and 5-keto reductase (5-KR) to give desired end products which include but are not limited to KLG and IA. In a preferred embodiment of the *in vivo* environment for the production of ASA intermediates, 5-KR activity is deleted in order to prevent the consumption of IA

30 If KLG is a desired intermediate, nucleic acid encoding DKGR is recombinantly introduced into the *Pantoea* fermentation strain. Many species have been found to contain DKGR particularly members of the *Coryneform* group, including the genera *Corynebacterium*, *Brevibacterium*, and *Arthrobacter*.

In some embodiments of the present invention, 2,5-DKGR from *Corynebacterium* sp. strain SHS752001 (Grindley *et al.*, 1988, *Applied and Environmental Microbiology* 54: 1770-
35 1775) is recombinantly introduced into a *Pantoea* strain. Production of recombinant 2,5

DKG reductase by *Erwinia herbicola* is disclosed in United States Patent No. 5,008,193 to Anderson et al. Other sources of DKG reductase are provided in Table I.

The fermentation may be performed in a batch process or in a continuous process. In a batch process, regardless of what is added, all of the broth is harvested at the same time. In a continuous system, the broth is regularly removed for downstream processing while fresh substrate is added. The intermediates produced may be recovered from the fermentation broth by a variety of methods including ion exchange resins, absorption or ion retardation resins, activated carbon, concentration-crystallization, passage through a membrane, etc.

B. *In vitro* biocatalytic environment

The invention provides for the biocatalytic production of ASA intermediates, e.g., KDG, DKG and KLG, from a carbon source in an *in vitro* or non-fermentative environment, such as in a bioreactor. The cells are first cultured for growth and for the non-fermentative process the carbon source utilized for growth is eliminated, the pH is maintained at between about pH 4 and about pH 9 and oxygen is present.

Depending upon the desired intermediate being produced, the process may require the presence of enzymatic co-factor. In a preferred embodiment disclosed herein, the enzymatic co-factor is regenerated. In some embodiments, KDG is the desired ASA intermediate produced, the bioreactor is provided with viable or non-viable *Pantoea citrea* host cells comprising a modification in a polynucleotide encoding an endogenous enzymatic activity that phosphorylates D-glucose at its 6th carbon and/or a modification in a polynucleotide encoding an enzymatic activity that phosphorylates D-gluconate at its 6th carbon. In this embodiment, the host cell also has a mutation in a gene encoding 2-keto-D-gluconate dehydrogenase activity. In this embodiment, the carbon source is biocatalytically converted through two productive steps, to KDG. In this embodiment, there is no need for co-factor regeneration.

When DKG is the desired ASA intermediate, the bioreactor is provided with viable or non-viable *Pantoea citrea* host cells comprising a modification in a polynucleotide encoding an endogenous enzymatic activity that phosphorylates D-glucose at its 6th carbon and/or a modification in a polynucleotide encoding an enzymatic activity that phosphorylates D-gluconate at its 6th carbon and a carbon source which is biocatalytically converted through three productive steps, to DKG. In this embodiment, there is no need for co-factor regeneration.

When KLG is the desired ASA intermediate, the bioreactor is provided with viable or non-viable *Pantoea citrea* host cells comprising a modification in a polynucleotide encoding

an endogenous enzymatic activity that phosphorylates D-glucose at its 6th carbon and/or a modification in a polynucleotide encoding an enzymatic activity that phosphorylates D-gluconate at its 6th carbon and a carbon source, such as D-glucose, which is biocatalytically converted through three productive steps, and one reducing step to KLG. In this embodiment, the reductase activity may be encoded by nucleic acid contained within the *Pantoea citrea* host cell or provided exogenously. In this embodiment, the first productive enzymatic activity requires an oxidized form of the co-factor and the reducing enzymatic activity requires a reduced form of co-factor. In a preferred embodiment disclosed herein, the *Pantoea citrea* cell is modified to eliminate the naturally occurring GDH activity and a heterologous GDH activity, such as one obtainable from *T. acidophilum*, *Cryptococcus uniguttalatus* or *Bacillus* species and having a specificity for NADPH⁺, is introduced into the *Pantoea* cell in order to provide a co-factor recycling system which requires and regenerates one co-factor. In this embodiment, the host cell further comprises nucleic acid encoding a 2,5-DKG reductase activity or the 2,5-DKG reductase is added exogenously to the bioreactor.

In another embodiment for making KLG, the bioreactor is charged with *Pantoea citrea* cells comprising a modification in nucleic acid encoding an endogenous enzymatic activity which phosphorylates D-glucose at its 6th carbon and/or in nucleic acid encoding an enzymatic activity that phosphorylates D-gluconate at its 6th carbon and further comprises nucleic acid encoding membrane-bound GDH, appropriate enzymes and cofactor, and D-gluconic acid is added which is converted to DKG. The reaction mixture is then made anaerobic and glucose is added. The GDH converts the glucose to GA, and the reductase converts DKG to KLG, while cofactor is recycled. When these reactions are completed, oxygen is added to convert GA to DKG, and the cycles continue.

In the *in vitro* biocatalytic process, the carbon source and metabolites thereof proceed through enzymatic oxidation steps or enzymatic oxidation and enzymatic reducing steps which may take place outside of the host cell intracellular environment and which exploit the enzymatic activity associated with the host cell and proceed through a pathway to produce the desired ASA intermediate. The enzymatic steps may proceed sequentially or simultaneously within the bioreactor and some have a co-factor requirement in order to produce the desired ASA intermediate. The present invention encompasses an *in vitro* process wherein the host cells are treated with an organic substance, such that the cells are non-viable, yet enzymes remain available for oxidation and reduction of the desired carbon source and/or metabolites thereof in the biocatalysis of carbon source to ASA intermediate.

The bioreactor may be performed in a batch process or in a continuous process. In a batch system, regardless of what is added, all of the broth is harvested at the same time.

In a continuous system, the broth is regularly removed for downstream processing while fresh substrate is added. The intermediates produced may be recovered from the fermentation broth by a variety of methods including ion exchange resins, absorption or ion retardation resins, activated carbon, concentration-crystallization, passage through a
5 membrane, etc.

In some embodiments, the host cell is permeabilized or lyophilized (Izumi *et al.*, *J. Ferment. Technol.* 61 (1983) 135-142) as long as the necessary enzymatic activities remain available to convert the carbon source or derivatives thereof. The bioreactor may proceed with some enzymatic activities being provided exogenously and in an environment wherein
10 solvents or long polymers are provided which stabilize or increase the enzymatic activities. In some embodiments, methanol or ethanol is used to increase reductase activity. In another embodiment, Gafquat is used to stabilise the reductase (see Gibson *et al.*, US Patent 5,240,843).

In some embodiments of the invention, a carbon source is converted to KLG in a
15 process which involves co-factor regeneration. In this enzymatic cofactor regeneration process, one equivalent of D-glucose is oxidized to one equivalent of D-gluconate, and one equivalent of NADP⁺ is reduced to one equivalent of NADPH by the catalytic action of GDH. The one equivalent D-gluconate produced by the GDH is then oxidized to one equivalent of 2-KDG, and then to one equivalent of 2,5-DKG by the action of membrane bound
20 dehydrogenases GADH and KDGDH, respectively. The one equivalent 2,5-DKG produced is then reduced to one equivalent of 2-KLG, and the NADPH is oxidized back to one equivalent of NADP⁺ by the action of 2,5-DKG reductase, effectively recycling the equivalent cofactor to be available for a second equivalent of D-glucose oxidation. Other methods of cofactor regeneration can include chemical, photochemical, and electrochemical
25 means, where the equivalent oxidized NADP⁺ is directly reduced to one equivalent of NADPH by either chemical, photochemical, or electrochemical means.

C. Host cells producing ASA

Any productive or reducing enzymes necessary for directing a host cell carbohydrate pathway into an ASA intermediate, such as, for example, KDG, DKG or KLG, can be
30 introduced *via* recombinant DNA techniques known to those of skill in the art if such enzymes are not naturally occurring in the host cell. Alternatively, enzymes that would hinder a desired pathway can be inactivated by recombinant DNA methods. The present invention encompasses the recombinant introduction or inactivation of any enzyme or intermediate necessary to achieve a desired pathway.

35 In some embodiments, *Enterobacteriaceae* strains that have been cured of a cryptic plasmid are used in the production of ASA, see PCT WO 98/59054.

- 31 -

In some embodiments, the host cell used for the production of an ASA intermediate is *Pantoea citrea*, for example, ATCC accession number 39140. Sources for nucleic acid encoding productive or reducing enzymes which can be used in the production of ASA intermediates in *Pantoea* species include the following:

5

Table I

<u>ENZYME</u>	<u>CITATION</u>
glucose dehydrogenase	Smith et al. 1989, Biochem. J. 261:973; Neijssel et al. 1989, Antonie Van Leuvenhoek 56(1):51-61
	Cha, et al, Appl. Environ. Microbiol 63(1), 71-76 (1997);
	Pujol, C.J., et al, Microbiol. 145, 1217-1226
gluconic acid dehydrogenase	Matsushita et al. 1979, J.Biochem. 85:1173; Kulbe et al.1987, Ann. N.Y. Acad Sci 6:552 (Los Angeles)
	Pujol, C.J., et al, J. of Bacteriol 63(1), 71-76 (1999)
	Yum, D, et al, J. of Bacteriol 183(8)2230- 2237
2-keto-D-gluconic acid dehydrogenase	Stroshane 1977 Biotechnol. BioEng 19(4) 459
2-keto gluconate reductase	J. Gen. Microbiol. 1991, 137:1479 Pujols, et al, J. of Bacterial. 182(8), (2000)
2,5-diketo-D-gluconic acid reductase	United States Patent Nos: 5,795,761; 5,376,544; 5,583,025; 4,757,012; 4,758,514; 5,008,193; 5,004,690; 5,032,514

25

30

35

D. Recovery of ASA Intermediates

Once produced, the ASA intermediates can be recovered and/or purified by any means known to those of skill in the art, including, lyophilization, crystallization, spray-drying, and electrodialysis, etc. Electrodialysis methods for purifying ASA and ASA intermediates such as KLG are described in for example, United States patent number 5747306 issued May 5, 1998 and United States patent number 4767870, issued August 30, 1998. Alternatively, the intermediates can also be formulated directly from the fermentation broth or bioreactor and granulated or put in a liquid formulation.

40

KLG produced by a process of the present invention may be further converted to ascorbic acid and the KDG to erythorbate by means known to those of skill in the art, see for example, Reichstein and Grussner, *Helv. Chim. Acta.*, 17, 311-328 (1934). Four stereoisomers of ascorbic acid are possible: L-ascorbic acid, D-araboascorbic acid
5 (erythorbic acid), which shows vitamin C activity, L-araboascorbic acid, and D-xyloascorbic acid.

E. Assay conditions

Methods for detection of ASA intermediates, ASA and ASA stereoisomers include
10 the use of redox-titration with 2,6 dichloroindophenol (Burton et al. 1979, J. Assoc. Pub. Analysts 17:105) or other suitable reagents; high-performance liquid chromatography (HPLC) using anion exchange (J. Chrom. 1980, 196:163); and electro-redox procedures (Pachia, 1976, Anal. Chem. 48:364). The skilled artisan will be well aware of controls to be applied in utilizing these detection methods.

15 Fermentation media in the present invention must contain suitable carbon substrates which will include but are not limited to monosaccharides such as glucose, oligosaccharides such as lactose or sucrose, polysaccharides such as starch or cellulose and unpurified mixtures from a renewable feedstocks such as cheese whey permeate, cornsteep liquor, sugar beet molasses, and barley malt. Additionally the carbon substrate may also be one-carbon
20 substrates such as carbon. While it is contemplated that the source of carbon utilized in the present invention may encompass a wide variety of carbon containing substrates and will only be limited by the choice of organism, the preferred carbon substrates include glucose and/or fructose and mixtures thereof. By using mixtures of glucose and fructose in combination with the modified genomes described elsewhere in this application, uncoupling
25 of the oxidative pathways from the catabolic pathways allows the use of glucose for improved yield and conversion to the desired ascorbic acid intermediate while utilizing the fructose to satisfy the metabolic requirements of the host cells.

Although it is contemplated that all of the above mentioned carbon substrates are suitable in the present invention preferred are the carbohydrates glucose, fructose or
30 sucrose. The concentration of the carbon substrate is from about 55% to about 75% on a weight/weight basis. Preferably, the concentration is from about 60 to about 70% on a weight/weight basis. The inventors most preferably used 60% or 67% glucose.

In addition to an appropriate carbon source, fermentation media must contain suitable
35 minerals, salts, vitamins, cofactors and buffers suitable for the growth or the cultures and promotion of the enzymatic pathway necessary for ascorbic acid intermediate production.

Culture conditions:

Precultures:

5 Typically cell cultures are grown at 25 to 32 ° C, and preferably about 28 or 29° C. in appropriate media. While the examples describe growth media used, other exemplary growth media useful in the present invention are common commercially prepared media such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth or Yeast medium (YM) broth. Other defined or synthetic growth media may also be used and the appropriate
10 medium for growth of the particular microorganism will be known by someone skilled in the art of microbiology or fermentation science.

 Suitable pH ranges preferred for the fermentation are between pH 5 to pH 8 where pH 7 to pH 7.5 for the seed flasks and between pH 5 to pH 6 for the reactor vessel.

 It will be appreciated by one of skill in the art of fermentation microbiology that, now
15 that Applicants have demonstrated the feasibility of the process of the present invention a number of factors affecting the fermentation processes may have to be optimized and controlled in order to maximize the ascorbic acid intermediate production. Many of these factors such as pH, carbon source concentration, and dissolved oxygen levels may affect the enzymatic process depending on the cell types used for ascorbic acid intermediate
20 production.

Batch and Continuous Fermentations:

 The present process employs a fed-batch method of fermentation for its culture systems. A classical batch fermentation is a closed system where the composition of the
25 media is set at the beginning of the fermentation and not subject to artificial alterations during the fermentation. Thus, at the beginning of the fermentation the media is inoculated with the desired organism or organisms and fermentation is permitted to occur adding nothing to the system. Typically, however, a "batch" fermentation is batch with respect to the addition of carbon source and attempts are often made at controlling factors such as pH and
30 oxygen concentration. In batch systems the metabolite and biomass compositions of the system change constantly up to the time the fermentation is stopped. Within batch cultures cells moderate through a static lag phase to a high growth log phase and finally to a stationary phase where growth rate is diminished or halted. If untreated, cells in the stationary phase will eventually die. Cells in log phase generally are responsible for the bulk
35 of production of end product or intermediate.

- 34 -

A variation on the standard batch system is the Fed-Batch system. Fed-Batch fermentation processes are also suitable in the present invention and comprise a typical batch system with the exception that the substrate is added in increments as the fermentation progresses. Fed-Batch systems are useful when catabolite repression is apt to inhibit the metabolism of the cells and where it is desirable to have limited amounts of substrate in the media. Measurement of the actual substrate concentration in Fed-Batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen and the partial pressure of waste gases such as CO₂. Batch and Fed-Batch fermentations are common and well known in the art and examples may be found in Brock, supra.

Although the present invention is performed in batch mode it is contemplated that the method would be adaptable to continuous fermentation methods. Continuous fermentation is an open system where a defined fermentation media is added continuously to a bioreactor and an equal amount of conditioned media is removed simultaneously for processing. Continuous fermentation generally maintains the cultures at a constant high density where cells are primarily in log phase growth.

Continuous fermentation allows for the modulation of one factor or any number of factors that affect cell growth or end product concentration. For example, one method will maintain a limiting nutrient such as the carbon source or nitrogen level at a fixed rate and allow all other parameters to moderate. In other systems a number of factors affecting growth can be altered continuously while the cell concentration, measured by media turbidity, is kept constant. Continuous systems strive to maintain steady state growth conditions and thus the cell loss due to media being drawn off must be balanced against the cell growth rate in the fermentation. Methods of modulating nutrients and growth factors for continuous fermentation processes as well as techniques for maximizing the rate of product formation are well known in the art of industrial microbiology and a variety of methods are detailed by Brock, supra.

It is contemplated that the present invention may be practiced using either batch, fed-batch or continuous processes and that any known mode of fermentation would be suitable. Additionally, it is contemplated that cells may be immobilized on a substrate as whole cell catalysts and subjected to fermentation conditions for ascorbic acid intermediate production.

Identification and Purification of ascorbic acid intermediates:

Methods for the purification of the desired ascorbic acid intermediate from fermentation media are known in the art.

The specific ascorbic acid intermediate may be identified directly by submitting the media to high pressure liquid chromatography (HPLC) analysis. Preferred in the present invention is a method where fermentation media is analyzed on an analytical ion exchange column using a mobile phase of 0.01N sulfuric acid in an isocratic fashion.

5

EXAMPLES

GENERAL METHODS

Materials and Methods suitable for the maintenance and growth of bacterial cultures were found in Manual of Methods for General Bacteriology (Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, eds), pp. 210-213. American Society for Microbiology, Washington, DC. or Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition (1989) Sinauer Associates, Inc., Sunderland, Mass. All reagents and materials used for the growth, and of bacterial cells were obtained from Difco Laboratories (Detroit, Mich.), Aldrich Chemicals (Milwaukee, Wis.) or Sigma Chemical Company (St. Louis, Mo.) unless otherwise specified.

Growth medium for the precultures or inoculum is commercially available and preparations such as Luria Bertani (LB) broth, Sabouraud Dextrose (SD) broth or Yeast medium (YM) broth are obtainable from GIBCO/BRL (Gaithersburg, Md.). LB-50amp is Luria-Bertani broth containing 50 .mu.g/ml ampicillin.

Fermentation Media:

Two basic fermentation media were prepared for use in the following examples, and identified as Seed Flask Media and Fermentation Media. These basic media were modified by altering the carbon source or by the addition of other reagents such as sulfite. The reagents useful for the respective media include KH_2PO_4 , K_2HPO_4 , $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, Difco Soytone, Sodium citrate, Fructose, $(\text{NH}_4)_2\text{SO}_4$, Nicotinic acid, $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$, and trace salts, including, but not limited to $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, $\text{MnSO}_4 \cdot \text{H}_2\text{O}$, and $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$; KH_2PO_4 , $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, $(\text{NH}_4)_2\text{SO}_4$, Mono-sodium glutamate, $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, $\text{MnSO}_4 \cdot \text{H}_2\text{O}$, $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$, $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$, Choline chloride, Mazu DF-204 (an antifoaming agent), Nicotinic acid, Ca-pantothenate and HFCS (42DE). HFCS can also be made according to the desired ratios of glucose to fructose, e.g., a fructose/glucose solution made of 27.3 g/L powdered fructose, 25.0 g/L powdered glucose.

35

- 36 -

Cells:

All commercially available cells used in the following examples were obtained from the ATCC and are identified in the text by their ATCC number. Recombinant *P. citrea* cells (ATCC39140) were used as ascorbic acid intermediate producers and were constructed as described in Examples 4 and 5. Enzymatic assays and genome analysis revealed that the strains MDP41 and DD6 lacked the genes encoding the glucokinase, gluconokinase and both enzymes whereas the wild-type strains contained genes encoding the glucokinase and/or gluconokinase enzymes.

10 Ascorbic acid intermediate analysis:

The presence of ascorbic acid intermediates, e.g., 2-KLG, was verified by running a HPLC analysis. Fermentation reactor vessel samples were drawn off the tank and loaded onto Dionex (Sunnyvale, CA, Product No. 043118) Ion Pac AS 10 column (4 mm times 250mm) connected to a Waters 2690 Separation Module and a Waters 410 Differential Refractometer (Milford, MA).

Methods of assaying for production of ascorbic acid intermediate

Methods for determining the yield, OUR, and CER were described earlier in the definition section.

20 Recombinant methods

Vector sequences

Expression vectors used the methods of the present invention comprise at least one promoter associated with the enzyme, which promoter is functional in the host cell. In one embodiment of the present invention, the promoter is the wild-type promoter for the selected enzyme and in another embodiment of the present invention, the promoter is heterologous to the enzyme, but still functional in the host cell. In one embodiment of the present invention, nucleic acid encoding the enzyme is stably integrated into the microorganism genome.

In some embodiments, the expression vector contains a multiple cloning site cassette which preferably comprises at least one restriction endonuclease site unique to the vector, to facilitate ease of nucleic acid manipulation. In a preferred embodiment, the vector also comprises one or more selectable markers. As used herein, the term selectable marker refers to a gene capable of expression in the host microorganism which allows for ease of selection of those hosts containing the vector. Examples of such selectable markers include but are not limited to antibiotics, such as, erythromycin, actinomycin, chloramphenicol and tetracycline.

A preferred plasmid for the recombinant introduction of non-naturally occurring enzymes or intermediates into a strain of Enterobacteriaceae is RSF1010, a mobilizable, but not self transmissible plasmid which has the capability to replicate in a broad range of bacterial hosts, including Gram - and Gram+ bacteria. (Frey et al., 1989, The Molecular
5 biology of IncQ plasmids. In: Thomas (Ed.), Promiscuous Plasmids of Gram Negative Bacteria. Academic Press, London, pp. 79-94). Frey et al. (1992, Gene 113:101-106) report on three regions found to affect the mobilization properties of RSF1010.

Transformation

10 General transformation procedures are taught in Current Protocols In Molecular Biology (vol. 1, edited by Ausubel et al., John Wiley & Sons, Inc. 1987, Chapter 9) and include calcium phosphate methods, transformation using DEAE-Dextran and electroporation. A variety of transformation procedures are known by those of skill in the art for introducing nucleic acid encoding a desired protein in a given host cell. A variety of host
15 cells can be used for recombinantly producing the pathway enzymes to be added exogenously, including bacterial, fungal, mammalian, insect and plant cells.

In some embodiments of the process, the host cell is an Enterobacteriaceae. Included in the group of Enterobacteriaceae are Erwinia, Enterobacter, Gluconobacter and Pantoea species. In the present invention, a preferred Enterobacteriaceae fermentation
20 strain for the production of ASA intermediates is a Pantoea species and in particular, Pantoea citrea. In some embodiments, the host cell is Pantoea citrea comprising pathway enzymes capable of converting a carbon source to KLG.

Identification of Transformants

Whether a host cell has been transformed can be detected by the presence/absence
25 of marker gene expression which can suggest whether the nucleic acid of interest is present. However, its expression should be confirmed. For example, if the nucleic acid encoding a pathway enzyme is inserted within a marker gene sequence, recombinant cells containing the insert can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with nucleic acid encoding the pathway enzyme under the
30 control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the enzyme as well.

Alternatively, host cells which contain the coding sequence for a pathway enzyme and express the enzyme may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA
35 hybridization and protein bioassay or immunoassay techniques which include membrane-

- 38 -

based, solution-based, or chip-based technologies for the detection and/or quantification of the nucleic acid or protein.

Additionally, the presence of the enzyme polynucleotide sequence in a host microorganism can be detected by DNA-DNA or DNA-RNA hybridization or amplification
5 using probes, portions or fragments of the enzyme polynucleotide sequences.

The manner and method of carrying out the present invention may be more fully understood by those of skill in the art by reference to the following examples, which examples are not intended in any manner to limit the scope of the present invention or of the claims directed thereto. All references and patent publications referred to herein are hereby
10 incorporated by reference.

EXAMPLES

Example 1.

Construction of a genomic library from *P. citrea* 139-2a

15 *P. citrea* genomic DNA was prepared using the DNA-Pure™ genomic DNA Isolation Kit (CPG, Lincoln Park, NJ). 50 micrograms of this DNA was partially digested with the restriction enzyme Sau3A accordingly the manufacturer recommendations (Roche Molecular Biochemicals, Indianapolis, IN). The products of the digestion were separated on a 1% agarose gel and the DNA fragments of 3-5 kilobases were purified from the gel using the
20 Qiaquick Gel extraction kit (Qiagen Inc. Valencia, CA). The resulting DNA was ligated with BamH1-linearized plasmid pBK-CMV (Stratagene, La Jolla, CA). A library of around 10xx different plasmids was obtained in this way.

Example 2.

Isolation of the structural gene for the glucokinase enzyme.

25 To select for a plasmid that carries the glucokinase gene from *P. citrea*, the genomic library (see above) was transformed into a *E. coli* strain devoid of the glucokinase gene (*glkA*) and the PTS transport system, strain NF9, *glk*⁻, (Flores et al., Nat. Biotech. 14, 620-623). After transformation, the cells were selected for growth on M9 media with glucose as the only carbon source. With this strategy, plasmids able to complement the *glk*⁻ or *pts*⁻
30 mutations were selected.

After 48 hrs. of incubation at 37 °C, many colonies were visible. Several of these colonies were further purified and their plasmids isolated and characterized by restriction analysis. It was found that all the plasmids contained a common DNA fragment.

- 39 -

After re-transforming these plasmids back into NF9, *glk*⁻, all of them allowed growth on M9-glucose media, corroborating that they were able to complement at least one of the mutations present in NF9, *glk*⁻.

Plasmid pMD4 was isolated in this way and contains an insert of around 3.9 kb. The
5 insert in this plasmid was sequenced and it was found that in a region of around 1010 bp, a gene with a strong similarity to the *E. coli glkA* gene was present. (SEQ ID 4.)

Example 3.

Inactivation of the glucokinase gene by homologous recombination.

10 The general strategy to inactivate genes by homologous recombination with a suicide vector has been delineated before (Miller and Mekalanos., J. Bacteriol. 170 (1988) 2575-2583). To inactivate the *glk* gene from *P.citrea* by this approach two plasmids were constructed: pMD5 and pMD6.

To construct pMD5, plasmid pMD4 was digested with the NcoI and SnaB1 restriction
15 enzymes accordingly manufacturer specifications. (Roche Molecular Biochemicals, Indianapolis, IN). The cohesive ends generated by these enzymes were blunt-ended with T4 polymerase using standard techniques. This DNA was ligated with a loxP-Cat-loxP cassette isolated from pLoxCat2 as a SspI-EcoRV DNA fragment. (Palmeros et al., Gene (2000) 247, 255-264.). This cassette codes for Chloramphenicol resistance. The ligation mixture
20 was transformed into TOP10 competent cell (Invitrogen, Carlsbad CA). selecting for growth on Chloramphenicol 10 micrograms/ml. Several colonies were obtained after 18 hr. incubation at 37 °C. The plasmids of some of these colonies were purified and characterized by restriction analysis. The presence of the loxP-Cat-loxP and the deletion of the DNA region between the NcoI and SnaB1 sites in the *glk* gene was confirmed. The
25 plasmid with these properties was named pMD5.

To construct pMD6, plasmid pMD5 was digested with the BamH1 and Ccl11 restriction enzymes. The DNA fragment containing the *glk* gene interrupted with the loxP-cassette was ligated to a EcoRV-Bsa1 DNA fragment isolated from plasmid pR6Kori1 (unpublished results). This fragment contains the R6K origin of replication and the
30 Kanamycin resistance gene. The ligation mixture was transformed into strain SY327 (Miller and Mekalanos., *ibid.*) and transformants were selected on plates containing kanamycin and chloramphenicol (20 and 10 micrograms/ml respectively). Several colonies were obtained after 24 hr. incubation at 37 °C. The plasmids of some of these colonies were purified and characterized by restriction analysis. The presence of the loxP-Cat-loxP and the R6K origin
35 was confirmed. The plasmid with these characteristics was named pMD6.

- 40 -

One characteristic of pMD6 and R6K derivatives in general, is that they can only replicate in strains that carry the *pir* gene from plasmid R6K (Miller and Mekalanos., *ibid.*). *P. citrea* does not contain the *pir* gene or sustains replication of pMD6. After transforming pMD6 into *P. citrea* 139-2a and selecting for Cm (R) strains, the proper gene replacement
5 by homologous recombination was obtained. The inactivation of the glucokinase gene was confirmed by assaying Glucokinase activity using the glucokinase-glucose-6-phosphate dehydrogenase coupled assay described by Fukuda et al., (Fukuda Y., Yamaguchi S., Shimosaka M., Murata K. and Kimura A. J. Bacteriol. (1983) vol. 156: pp. 922-925). The *P. citrea* strain where the glucokinase inactivation was confirmed was named MDP4.
10 Further confirmation of the inactivation of the glucokinase gene was generated by comparing the size PCR products obtained using chromosomal DNA from 139-2a or MDP4 strains and primers that hybridize with the glucokinase structural gene (SEQ. ID. 8, SEQ. ID. 9). With this approach, the size of the PCR products should reflect that the *loxP*-Cat-*loxP* cassette was cloned in the glucokinase structural gene.

15

Example 4.

Removal of the chloramphenicol resistance marker in MDP4

After overnight growth on YENB medium (0.75% yeast extract, 0.8% nutrient broth) at 30°C, *P. citrea* MDP40 in a water suspension was electrottransformed with plasmid pJW168
20 (. (Palmeros et al., *Gene* (2000) 247, 255-264.). which contained the bacteriophage P1 Cre recombinase gene (IPTG-inducible), a temperature-sensitive pSC101 replicon, and an ampicillin resistance gene. Upon outgrowth in SOC medium at 30°C, transformants were selected at 30°C (permissive temperature for pJW168 replication) on LB agar medium supplemented with carbenicillin (200 µg/ml) and IPTG (1 mM). Two serial overnight transfers
25 of pooled colonies were carried out at 35°C on fresh LB agar medium supplemented with carbenicillin and IPTG in order to allow excision of the chromosomal chloramphenicol resistance gene via recombination at the *loxP* sites mediated by the Cre recombinase (Hoess and Abremski, *J. Mol. Biol.*, 181:351-362). Resultant colonies were replica-plated on to LB agar medium supplemented with carbenicillin and IPTG and LB agar supplemented
30 with chloramphenicol (12.5 µg/ml) to identify colonies at 30°C that were carbenicillin-resistant and chloramphenicol-sensitive indicating marker gene removal. An overnight 30°C culture of one such colony was used to inoculate 10 ml of LB medium. Upon growth at 30°C to OD (600 nm) of 0.6, the culture was incubated at 35°C overnight. Several dilutions were plated on prewarmed LB agar medium and the plates incubated overnight at 35°C (the non-
35 permissive temperature for pJW168 replication). Resultant colonies were replica-plated on

- 41 -

to LB agar medium and LB agar medium supplemented with carbenicillin (200 µg/ml) to identify colonies at 30°C that were carbenicillin-sensitive, indicating loss of plasmid pJW168. One such glK mutant, MDP41, was further analyzed by genomic PCR using primers SEQ ID NO:5 and SEQ ID NO:6 and yielded the expected PCR product (data not shown).

5

Example 5.

Inactivation of the gluconate kinase gene by homologous recombination.

The general strategy utilized to inactivate the gluconate kinase gene of *P. citrea* is presented in Fig.9, was in essence the same used to inactivate the glucokinase gene as described in example 3. Briefly, after isolating and sequencing a plasmid that allowed a *E.coli* strain Δ gntK Δ idnK, to grow using gluconate as the only carbon source (data not shown); a DNA fragment containing the structural gene for the gluconate kinase gene was generated by PCR using primers SEQ. ID NO: 10 and SEQ. ID NO:11. This approximately 3 kb PCR product was cloned in a multicopy plasmid containing an R6K origin of replication..

A unique PstI restriction site located in the gluconate kinase structural gene as shown in SEQ. ID NO: 2, was utilized to insert a loxP-Cat-loxP cassette. This construction was transferred to the chromosome of the *P. citrea* strain MDP41 by homologous recombination. The correct interruption of the gluconate kinase with the loxP-Cat-loxP cassette was confirmed by PCR, using primers SEQ ID NO:11 and SEQ ID NO:12.

The new strain, with both glucose and gluconate kinase inactivated was named MDP5. This strain still contains the Cat marker inserted in the gluconate kinase structural gene. By repeating the procedure described in example 4, a marker-less strain was obtained and named DD6.

25 Experimental 6

The following illustrates the benefit of a double delete host cell (glucokinase and gluconokinase deleted *Pantoea* host cells) in terms of O₂ demand.

Seed Train:

A vial of culture stored in liquid nitrogen is thawed in air and 0.75 mL is added to a sterile 2-L Erlenmeyer flasks containing 500 mL of seed medium. Flasks are incubated at 29 °C and 250 rpm for 12 hours. Transfer criteria is an OD₅₅₀ greater than 2.5.

Seed flask medium

A medium composition was made according to the following:

35	Component	Amount
----	-----------	--------

- 42 -

	KH_2PO_4	12.0 g/L	
	K_2HPO_4	4.0 g/L	
	$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	2.0 g/L	
	Difco Soytone	2.0 g/L	
5	Sodium citrate	0.1 g/L	
	Fructose	5.0 g/L	
	$(\text{NH}_4)_2\text{SO}_4$	1.0 g/L	
	Nicotinic acid	0.02 g/L	
	$\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$	5 mL/L (of a 0.4 g/L stock solution)	
10	Trace salts	5 mL/L (of the following solution: 0.58 g/L $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, 0.34 g/L $\text{MnSO}_4 \cdot \text{H}_2\text{O}$, 0.48 g/L $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$)	

The pH of the medium solution was adjusted to 7.0 ± 0.1 unit with 20% NaOH. Tetracycline HCl was added to a final concentration of 20 mg/L (2 mL/L of a 10 g/L stock solution). The resulting medium solution was then filter sterilized with a 0.2μ filter unit. The medium was then autoclaved and 500 mL of the previously autoclaved medium was added to 2-L Erlenmeyer flasks.

Production Fermentor

20 Additions to the reactor vessel prior to sterilization

	Component	Conc
	KH_2PO_4	3.5 g/L
	$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	1.0 g/L
	$(\text{NH}_4)_2\text{SO}_4$	0.92 g/L
25	Mono-sodium glutamate	15.0 g/L
	$\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$	5.79 mg/L
	$\text{MnSO}_4 \cdot \text{H}_2\text{O}$	3.44 mg/L
	$\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$	4.70 mg/L
	$\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$	2.20 mg/L
30	Choline chloride	0.112 g/L
	Mazu DF-204	0.167 g/L

The above constituted media was sterilized at 121°C for 45 minutes.

35 After tank sterilization, the following additions were made to the fermentation tank:

Component	Conc
-----------	------

- 43 -

Nicotinic acid 16.8 mg/L

Ca-pantothenate 3.36 mg/L

HFCS (42DE) 95.5 g/L (gluconate or glucose if desired as the particular starting substrate)

5

The final volume after sterilization and addition of post-sterilization components was 6.0 L. The so prepared tank and medium were inoculated with the full entire contents from seed flask prepared as described to give a volume of 6.5 L.

Growth conditions were at 29 °C and pH 6.0. Agitation rate, back pressure, and air
10 flow are adjusted as needed to keep dissolved oxygen above zero.

Results

The oxidative pathway for ascorbic acid intermediates is depicted in Fig. 10. By determining the amount of carbon dioxide produce (CER), one can calculate the amount of
15 carbon utilized by the catabolic pathway and thus measure the uncoupling of the catabolic and productive (oxidative) pathways since the sole source of carbon for CO₂ is from the carbon substrate, no additional CO₂ having been supplied into the reactor vessel. When the wild-type organism was utilized in the fermentation process, 63% of the glucose was converted to an ascorbic acid intermediate, while 37% was converted, as measured by the
20 CER, to catabolic products (Fig. 12). In the second phase of the study, the nucleic acid encoding glucokinase expression was run under conditions of the wild-type. As shown in Fig. 13A, CO₂ evolution decreased to about 18%, as measured by CER. Thus glucose catabolism was reduced, but not completely uncoupled. In an attempt to ascertain the source, i.e. the pathway wherein the carbon substrate was being diverted to the catabolic
25 pathway, gluconic acid was provided as the sole carbon source. As shown in Fig. 13B in comparison with Fig. 13A, gluconic acid was catabolized at about the same rate as if glucose had been the carbon substrate. (83% gluconate converted to ascorbic acid intermediate v. 17% of the gluconic acid converted to the catabolic pathway (as measured by CER). See also Table 2:

30

35

TABLE 2

strain	Fraction of Glucose converted to		Fraction of Gluconate converted to	
	Metabolism	DKG	Metabolism	DKG
Wild-type	0.37	0.63	--	--
Glucokinase delete (glkA)	0.18	0.82	0.17	0.83
Gluconokinase delete (gntK)	0.24	0.76	0.02	0.98

A last phase of the study was provided by the examination of the OUR and CER of a host cell having the genomic encoding for glucokinase and gluconokinase deleted from the host cell genome. Figure 14 depicts 3% glucose was converted to CO₂, whereas a control (wild-type) exhibited a 43% glucose to CO₂ yield. As a result, it appears that the wild-type exhibited a high catabolism of glucose by the catabolic pathway, which resulted in reduced yield and a high oxygen requirement. However, a dual deletion of glucokinase and gluconokinase essentially inactivated catabolism to less than 10 percent, less than 5 per cent and particularly 3 or less % of the initial carbon substrate.

Conclusions

The double mutant of glucokinase and gluconokinase appeared to shunt almost all of the glucose to 2,5-DKG, about 98%.

EXAMPLE 7.

Production of glycerol from fructose.

To demonstrate that *Pantoea citrea* can be used to produce chemical compounds derived from fructose, glycerol was produced using the approach described by Empatage et al., [Empatage, M., Haynie, S., Laffend, L., Pucci, J. and Whited, G. Process for the biological production of 1,3-propanediol with high titer.

Patent: WO 0112833-A 41 22-FEB-2001; E.I. DU PONT DE NEMOURS AND COMPANY ; GENENCOR INTERNATIONAL, INC.]. Briefly, this approach uses two enzymes from yeast to convert dihydroxyacetone phosphate (DHAP) into glycerol as shown in the following reaction:

The genes for the GPD1 and GPP2 enzymes were cloned in a multicopy plasmid pTrc99 under the control of the Trc promoter (Empatage et al., 2001). This plasmid (pAH48)

is able to produce high levels of both enzymes. The inventors recognized that to produce glycerol in *P. citrea*, it was desirable to eliminate or reduce the natural ability of the strain to assimilate glycerol. A common glycerol catabolic pathway in many bacteria, is through the action of the glycerol kinase [Lin E.C.. Ann. Rev. Microbiol. 1976. 30:535-578. Glycerol dissimilation and its regulation in bacteria]. The inventors found that the *P. citrea* was able to grow in media containing glycerols as the only carbon source. Furthermore, inspection of the *P. citrea* genome sequence, showed that it possesses a glycerol kinase gene, very similar to the *glkA* gene from *E.coli*.

Thus, to eliminate the glycerol kinase activity, the structural gene of this enzyme (gene *glpK*) was inactivated. This was accomplished as described in Examples 3 and 5 (inactivation of glucokinase and gluconokinase genes). Briefly, a 2.9 kb DNA fragment containing the *glpK* gene and flanking sequences, was obtained by PCR using chromosomal DNA from *P. citrea* and the primers disclosed in SEQ ID. *glpK1* and SEQ ID. *glpK2*. This 2.9 kb DNA fragment was cloned in a R6K vector as indicated in Examples 3 and 5. The DNA sequence of the *glpK* gene is shown in SEQ ID. ____, and the protein sequence of GlpK is shown in SEQ ID. ____.

Inspection of the *glpK* DNA sequence showed the presence of a *Hpa1* site, which was chosen to insert the *LoxP*-Cat-*LoxP* cassette. Once the desired plasmid construction was obtained, the *glpK* interruption was transferred to the chromosome of *P. citrea* strain 139-2a ps-, by homologous recombination as described in example 3 and 5. The resulting *P. citrea glpK:: Cm* strain was named MDG1.

Once the interruption of the *glpK* gene in the *P.citrea* genome was confirmed, the effect of this mutation was evaluated. For such a purpose, strain MDG1 was grown in minimal media M9 containing glycerol 0.4% as the only carbon source. After incubating the cells for 48 hours at 30 °C, no growth was observed, indicating that strain MDG1 lost the ability to utilize glycerol as a carbon source.

Strain MDG1 was transformed with plasmid pAH48 (Emptage et al., 2001), and the resulting strain MDG2, was tested for its capacity to produce glycerol using fructose as the only carbon source. This was accomplished by incubating the strain in minimal media containing 2% fructose as the only carbon source. After incubating the cells for 24 hours at 30 °C, a sample was collected and analyzed by HPLC as described by Emptage et al. (2001). By doing this, it was found that strain MDG1 did not produce any glycerol, while strain MDG2 produced 1.36 g/L of glycerol. These results demonstrated that *P. citrea* was able to divert a substantial part of fructose into the formation of glycerol.

Various other examples and modifications of the foregoing description and examples will be apparent to a person skilled in the art after reading the disclosure without departing

- 46 -

from the spirit and scope of the invention, and it is intended that all such examples or modifications be included within the scope of the appended claims. All publications and patents referenced herein are hereby incorporated by reference in their entirety.

CLAIMS

We claim:

1. A process for producing a product in a recombinant host cell comprising, culturing a host cell capable of producing said product in the presence of a carbon source under conditions suitable for the production of said product wherein said host cell comprises productive and catabolic pathways, wherein said pathways are uncoupled during part or all of said culturing.
2. The process of claim 1 wherein said productive pathway and said catabolic pathway are uncoupled during said culturing.
3. The process of claim 2 wherein said productive pathway is in said host cell membrane.
4. The process of claim 2 wherein said catabolic pathway is intracellular.
5. A method of enhancing the production of an end-product from a carbon source comprising,
 - a) obtaining an altered bacterial strain which comprises inactivating a chromosomal gene in a bacterial host strain,
 - b) culturing said altered bacterial host strain under suitable conditions, and
 - c) allowing the production of an end-product from the carbon source, wherein the production of said end-product is enhanced compared to the production of the end-product by an unaltered bacterial host strain.
6. The method of claim 5, wherein the ascorbic acid intermediate is selected from the group consisting of gluconate, 2-keto-D-gluconate, 2,5-diketo-D-gluconate, 2-keto-L-gulonic acid, L-iodonic acid, erthorbic acid, and tartrate.
7. The method of claim 6, wherein the ascorbic acid intermediate is 2,5-diketo-D-gluconate.
8. The method of claim 5, wherein said end-product is selected from the group consisting of ribose, riboflavin, and nucleotides.

- 48 -

9. The method of claim 5, wherein said altered bacterial strain is obtained by the inactivation of a *glk* chromosomal gene.

10. The method of claim 5, wherein said altered bacterial strain is obtained by the inactivation of a *gntk* chromosomal gene.

11. The method of claim 5, wherein said altered bacterial strain is obtained by the inactivation of a *glk* and a *gntk* chromosomal gene.

12. The method of claim 5, wherein said bacterial strain is *Pantoea*.

13. The method of claim 12, wherein said bacterial strain is *Pantoea citrea*.





FIG. 1

2 / 21

**FIG. 2**

3 / 21




FIG._3

4 / 21

DNA sequence of the Glucokinase structural gene from *P. citrea*. The recognition site for the restriction enzymes *Nco*I (CCATGG) and *Sna*BI (TACGTA) are highlighted.

ATGACAAACTATGCCTTGGTCGGCGATGTAGGCGGAACTAACGCCCCGCTTGCGTTGTG'
 GATGTGACTGACGGCAGCATCTCGCAGGCCAAAACCTTTTCAACCGAGGATTACCAGAG'
 CTGGAAGATGTTATTCGTGAGTATCTGGCGGATCAACAAGCCATCACCTGTGCATCTAT'
 GCCATCGCCTGTCCGGTGAAAGATGACTGGATTGAAATGACTAATCATAGCTGGGCGTT'
 TCTATCAGTGAGATGAAACAAAATCTCGGGCTGGAACATCTGGAAGTGATTAACGATT'
 ACTGCGGTCTCCATGGCAATTCCAATGCTGGGCAGTGACGATGTCATTTCAGTTTCGGCGG'
 GGTGCACCGGTAAAAGATAAACCGATAGCTATCTATGGTGCCGGAACAGGACTGGGGGT'
 AGCCATCTGGTTCATGTCAACAAACACTGGGTCAGCTTGCCTGGTGAAGGCGGACATGT'
 GATTTACCTGTGGTACCGAAGAAGAAGACATGATCATGAGTGTGCTGCGTGCAGAACG'
 GGCCGGGTGTCAGCTGAACGGGTGCTGTCAGGAAAAGGTCTGGTGAATATTTACCGGGC'
 ATTGTGATTTCTGACAACCGTGTTCTGAACGTCTGCAACCTCAGGACGTAACCGAGCG'
 GCATTATCCGGAAGCTGTACTGACTGTCGTCGTGCACTGTCATTGTTCTGTGTGATTAT'
 GGACGTTTTGGCGGGAACCTGGCCCTGACACTTGAACCTTCGGTGGGGTGTATATTGC'
 GCGGAATTGTTCCACGCTTCCTGCAGTTCTTTAAAGCCTCCGGTTTCCGTGCTGCTTT'
 GAAGATAAGGGACGTTTCCGTTCTTACGTACAGGATATTCCGGTCTATCTGATTACCCA'
 GATCAGCCGGGGCTGCTGGGTGCCGGTGCCCATATGCGCCAGACTTTAGGGATGGAAC'
 TAA

FIG. 4

Protein sequence of the Glucokinase gene from *P. citrea*.

MTNYALVGDVGGTNARLALCDVTDGSISQAKTFSTEDYQSLEDVIREYLAQQAITCASI
 AIACPVKDDWIEMTNHSAFSSISEMKQNLGLEHLEVINDFTAVSMAIPMLGSDDVIQFGG
 GAPVKDKPIAIYGAGTGLGVSHLVHVNKHVSLPGEKGHVDFTCGTEEDMIMSVLRAER
 GRVSAERVLSGKGLVNIYRAIVISDNRVPERLQPDVTERALSGSCTDCRRALSLFCVIM
 GRFGGNLALTLGTFGGVYIAGGIVPRFLQFFKASGFRAAFEDKGRFRSYVQDIPVYLITH
 DQPGLLGAGAHMRQTLGMEL

FIG. 5

5 / 21

DNA sequence of the Gluconate kinase structural gene from *P. citrea*. The recognition site for the restriction enzyme *Pst* I (CTGCAG) is highlighted.

ATGAGTACAGCTTCTTCAAATCATCATGTGTTTATCCTGatgGGCGTTTCCGGCAGCGGA
AAGTCGGTGGTCGCCAATCGTGTCTCTTACCAGTTGCAAACCGCATTCTTGATGGTGAC
TTTCTGCATCCCAGAGCGAACATCATGAAAATGGCTGACGGGCATCCGCTCAATGATCAG
GATCGTCAACCCTGGCTGCAGGCCATTAATGATGCGGCTTTTGCTATGCAGCGGACCCAG
GCTGTATCGTTAATTGTGTGTTTCGTCACTGAAAAAAGTTATCGCGATATTCTTCGTGAA
GGTAACAGCAATCTTAAGTTTGTATTATCTGAAAGGTGACTTCGATACCATCGAATCGCGT
CTTAAAGCCCGCAAGGGACACTTCTTCAAACCCGCCATGCTGGTAACACAATTCGCAACT
CTCGAAGAGCCGACCCCGGATGAAACTGATGTCCTCACGGTGGATATCCGGCAGTCGCTG
GATGAGGTTGTTGCTGCCACGGTAGAAGCGATCAAACACGCAATTCAGTAA

FIG._6

Protein sequence of the Glucokinase gene from *P. citrea*.

MSTASSNHVFIILMGVSGSGKSVVANRVSYQLQTAFLDGDFLHPRANIMKMADGHPLNDQ
DRQPWLQAINDAAFAMQRTQAVSLIVCSSLKKSRYRDILREGNSNLKFVYLKGDFTIESR
LKARKGHFFKPAMLVTFATLEEPTPDETDVLTVDIRQSLDEVVAATVEAIKHAIQ

FIG._7

6 / 21

SEQ. ID NO: 8

Name: glk 30

5'—TTTTC AACCGAGGATTAC CAGAGC—3'

SEQ. ID NO: 9

Name: glk 31

5'—CACGGCGCAGGAATGATACAGAGA—3'

SEQ. ID NO: 10

Name: gnt 1

5'—GGGAAGGTTCTGATGTGTCCGTG—3'

SEQ. ID NO: 11

gnt 2

5'—GCCGGTTGCAGCGCGTGACCGC—3'

SEQ. ID NO: 12


Name: pcgnt 3

5'—ACTAAAAGGGTACGGTGTCAGAGA—3'


SEQ. ID NO: 13

Name: pcgnt 4


5'—GTGTTGCGGTACTTATCATTATTA—3'

FIG. 8**FIG. 9**

7 / 21




8 / 21

**FIG. 11**



9 / 21

Net Reactions During Fermentation


- Glucose + 1.5 O₂ = DKG
- Glucose/Fructose = 6 CO₂ + 12 NAD(P)H
- DKG + NADPH = KLG + NADPH = Idonate
- DKG = 6 CO₂ + 9 NAD(P)H
- NAD(P)H + 0.5 O₂ = H₂O
- Glucose/Fructose + 0.732 NH₃ + 2.16 O₂ =
3.66 Biomass + 2.34 CO₂ + 3.80 H₂O

FIG._ 12**FIG._ 13**

10 / 21

**FIG. 14****FIG. 15**

11 / 21

**FIG. 16**

12 / 21




FIG. 17

13 / 21




FIG. 18




FIG. 20

16 / 21




FIG. 21





FIG.-22



19 / 21





FIG..24

20 / 21

**FIG._25**

GlpK1
5' TGCAGTTTCAATGGGTGTTTA 3'

GlpK2
5' TGTCCGGCATGCAGGTCAGA 3'

FIG._26

21 / 21

ATG- ACTAACGCTGAAAACAAATACATTGTTGCACTGGACCAGGGAACCACCAGCTCACGA
GCGGTAGTACTGGATCACGATGCAAATATTATCGCGGTTTCACAACGTGAATTTACTCAG
CACTATCCTAAAAACAGGCTGGGTTGAGCATGACCCGATGGATATCTGGGCAACCCAGAGT
TCAACTCTGGTAGAAGTACTGGCACACGCCGATATTTCGTTCTGATCAGATTGCGGCGATT
GGTATTACTAACCAGCGTGAAACCACCATCGTCTGGGATAAGAAAACCGGCAAGCCTGTC
TATAACGCAATTGTCTGGCAGGACCCACGCACCGCTGACTACTGCTCAAACTGAAAAAA
GAAGGTCTTGAAGAATATATTGAGAAGACGACCGGGCTTGTGATTAACCCTTACTTCTCC
GGAACCAAATAAAATGGATTCTGGACAATGTGGAAGGTGCCCGGGATCGAGCCAAACGT
GGGGAAC TGTTATTTGGTACCGTTGACACCTGGCTGGTCTGGAAAATGACTCAGGGTCGT
GTGCATGTTACCGACTTTACCAATGCTTCACGTACCATGATATTTGATATTCACAATCTG
AAGTGGGATGACCGTATGCTGGACATCCTTGATATTTCCACGTGAAATGCTGCCAGAAGTT
AAAGCATCTTCTGAAGTTTACGGGCAGACAAACATCGGTGGTAAAGGCGGAACCCGTATT
CCGATCGCCGGGATCGCTGGTGATCAGCAGGCGGCTTTATACGGCCAGCTCTGTGTGCAA
CCAGGTATGGCGAAGAATACGTATGGTACCGGCTGCTTTATGTTAATGAATACCGGTACA
GAAGCAGTAGCTTCTACTCATGGCCTGCTGACAACAATTGCCTGCGGTCCACGGGGTGAA
GTTAACTATGCGCTGGAAGGTGCAGTCTTTATTGGCGGTGCTTCCATTCAATGGCTGCGT
GATGAGATGAAACTGTTCTCTGAAGCTTTAGACTCTGAATATTTGCCACCAAAGTAAAA
GACTCTAACGGGGTTTATATGGTGCCGGCATTACCGGTTTAGGCGCTCCGTACTGGGAC
CCATATGCCCGTGGAGCAATTTTTGGCCTGACCCGCGGAACCAATGCTAACCATATTATC
CGCGCTACTCTGGAATCTATTGCCTACCAGACTCGCGACGTGCTGGAAGCAATGCAGAAT
GATGCGAATACCCGTCTGCAGTCATTGCGGGTAGATGGTGGCGCTGTGGCGAATAATTTCT
CTGATGCAATTCCAGTCCGATATTCTCGGAACACGGGTTGAGCGTCCGGAAGTTCTGTA
GTCACCGCTCTTGGAGCTGCCTATCTGGCCGGGCTGGCAGTTGGATTCTGGAAAGATCTG
GATGAAGTCCGTTGAAAGCGGTTATTGAGCGCGAGTTCCGCCCTTCAATCGAAACGACT
GAACGTAACTTCCGTTATGCCGGCTGGAAAAAAGCTGTTTCCCGCGCCCTGCGCTGGGAA
GATGAAAACGAACAA-TAA

FIG._27

MTNAENKYIVALDQGTSSRAVVLDDHANI IAVSQREFTQHYPKTGWVEHDPMDIWATQ
SSTLVEVLAHADIRSDQIAAIGITNQRETTIVWDKKTGKPVYNAIVWQDPRTADYCSKL
KREGLEEYIQKTTGLVINPYFSGTKIKWILDNVEGARDRAKRGELLFGTVDTWLVWKMT
QGRVHVTDFTNASRTMIFDIHNLKWDDRMLDILDIPREMLPEVKASSEVYGQTNIGGKG
GTRIP IAGIAGDQQAALYGQLCVQPGMAKN TYGTGCFMLMNTGTEAVASTHGLLT TIAC
GPRGEVNYALEGAVFIGGASIQWLRDEMCLFSEALDSEYFATKVKDSNGVYMVPAFTGL
GAPYWDPFYARGAIFGLTRGTNANH IIRATLES IAYQTRDVLEAMQNDANTRLQSLRVDG
GAVANNFLMQFS DILGTRVERPEVREVTALGAAYLAGLAVGFWKDLDEVRSKAVIERE
FRPSIETTERNFRYAGWKKA VSRALRWEDENEQ

FIG._28

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/081631 A3

- (51) International Patent Classification⁷: C12N 9/00, 9/12, 1/20, C07H 21/04
- (21) International Application Number: PCT/US02/10575
- (22) International Filing Date: 4 April 2002 (04.04.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/281,618 4 April 2001 (04.04.2001) US
60/282,259 5 April 2001 (05.04.2001) US
- (71) Applicant (*for all designated States except US*): GENENCOR INTERNATIONAL, INC. [US/US]; 925 Page Mill Road, Palo Alto, CA 94304 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): DODGE, Timothy, C. [US/US]; 1384 Bellingham Way, Sunnyvale, CA 94010 (US). VALLE, Fernando [MX/US]; 1015 Cadillac Way, Apt. 212, Burlingame, CA 94010 (US).
- (74) Agent: ITO, Richard, T.; GENENCOR INTERNATIONAL, INC., 925 Page Mill Road, Palo Alto, CA 94304 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 28 November 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 02/081631 A3

(54) Title: UNCOUPLED PRODUCTIVE AND CATABOLIC HOST CELL PATHWAYS

(57) Abstract: The invention provides methods for producing products comprising improved host cells genetically engineered to have uncoupled productive and catabolic pathways. In particular, the present invention provides host cells having a modification in nucleic acid encoding an endogenous enzymatic activity that phosphorylates D-glucose at its 6th carbon and/or a modification of nucleic acid encoding an enzymatic activity that phosphorylates D-gluconate at its 6th carbon. Such improved host cells are used for the production of products, such as, ascorbic acid intermediates. Methods for making and using the improved host cells are provided. Nucleic acid and amino acid sequences for glucokinase and gluconokinase are provided.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/10575

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 9/00, 9/12, 1/20; C07H 21/04

US CL : 435/183, 194, 252.3; 536/23.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/183, 194, 252.3; 536/23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN, MEDLINE, WEST

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 087 015 A2 (DEGUSSA-HULS AKTIENGESELLSCHAFT) 28 March 2001 (28.03.2001), see entire document.	1-5, and 8
X	US 5,032,514 (ANDERSON et al.) 16 JULY 1991 (16.07.1991), see entire document	6 and 7
X	EP 0 955 368 A2 (AJINOMOTO CO, LTD.) 10 NOVEMBER 1999 (10.11.1999), see entire document	12 and 13
A	WO 99/55877 A1 (HOLLAND SWEETENER COMPANY V.O.F.) 04 NOVEMBER 1999 (04.11.1999), see entire document.	9-11

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

B earlier application or patent published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

A document member of the same patent family

Date of the actual completion of the international search

11 July 2002 (11.07.2002)

Date of mailing of the international search report

17 SEP 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Valerie Bell-Harris for
Christian Fronda

Telephone No. (703)308-0196